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Abbreviations 
 
2-AG   2-Arachidonylglycerol 
   (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic acid,  
   2-hydroxy-1-(hydroxymethyl) ethyl ester 
2-LinoG  2-linoleoylglycerol 
2-PalmG  2-palmitoylglycerol 
ACPA   Arachidonylcyclopropylamide 
   N-(Cyclopropyl)-5Z,8Z,11Z,14Z-eicosatetraenamide 
AEA   Arachidonylethanolamide,  
   N-(2-Hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide 
AM-630  6-Iodo-2-methyl-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl(4-  
   methoxyphenyl)methanone 
APS   Ammonium persulfate 
bp   Basepair 
CB1
   
Cannabinoid receptor 1  
CB2
   
Cannabinoid receptor 2  
CDP Star  Disodium 4-chloro-3-(methoxy spiro {1,2-dioxethan- 3,2-  
   (5-chloro)tricyclo[3.3.1.13,7] decan}-4-yl) phenylphosphate 
CFP   Cyan fluorescent protein 
CNS   Central nervous system 
CP55,940  (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4- 
   (3-hydroxypropyl) cyclohexanol 
cAMP   Cyclic adenosine-3’, 5’-monophosphate 
DMSO   Dimethylsulfoxide  
DNFB   2,4-Dinitroflurobenzene 
dNTP   Deoxynucleotides 
dsRed   Discosoma sp. red fluorescent protein 
EDTA   Disodium ethylendiamine tetraacetic acid 
EGTA   Ethylenglycol-bis(-β-aminoethylether) N,N,N’,N’ tetra acetic acid 
ES cell   Embryonic stem cell 
Em   Molar extinction coefficient 
Erk   Extracellular signal-regulated kinases 
eCFP   Enhanced cyan fluorescent protein  
eGFP   Enhanced green fluorescent protein 
FAAH   Fatty acid amide hydrolase 
   Abbreviations 
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FIAU    2´-Deoxy-2´-fluoro-β-d-arabinofuranosyl-5-iodouracil 
GM-CSF   Granulocyte monocyte colony stimulating factor 
GPCR   G protein coupled receptor 
HBSS    Hanks balanced salt solution 
HEPES  N-2-Hydroxyethylpiperazin-N’-2-ethansulfonic acid 
HSV-TK   Herpes simplex virus - thymidine-kinase 
HU-210  (6aR,10aR)-3-(1,1’-dimethylheptyl)-6a,7,10,10a-tetrahydro-1- 
   hydroxyl -6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol  
HU-308  4-[4-(1,1-diemethylheptyl)-2,6-dimethoxyphenyl]-6,6-  
   dimethylbicyclo [3.1.1]hept-2-ene-2-methanol 
i.p.       Intra peritoneal 
JTE-907  [N-(benzo[1,3]dioxol-5ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-  
   1,2-dihydroquinoline-3-carboxamide] 
LIF    Leukaemia inhibitory factor 
loxP    Locus of X-cross of P1 
MOPS   3-Morpholino propan sulfonic acid 
NE   Noladine ether 
MAPK   Mitogen-activated protein kinases  
Sch.336  N-[1(S)-[4-[[4-methoxy-2-[(4-methoxyphenyl)sulfonyl]phenyl]- 
   sulfonyl]phenyl]ethyl]methanesulfonamide 
SDS    Sodium dodecyl sulfate 
SSC    Saline sodium citrate solution 
TAE    Tris-acetate EDTA 
TEMED   N,N,N´,N´ -Tetramethylethylendiamine  
TPA   tetradecanoyl 13-acetate 
Tris    2-amino-2-hydroxymethyl-1,3-propanediol  
Tween   Tween 20, Polyoxyethylenesorbitan Monolaurate 
U    Unit (s) 
WIN   WIN 55,212-2        
   R(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo- 
   [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenyl-methanonmesylate 
WT   Wild type 
Δ9-THC   Delta-9-tetrahydrocannabinol, 
   (R,R)-5,11-Diethyl-5,6,11,12-tetrahydro-2,8-chrysenediol
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  Introduction 
                                                  1
1 Introduction 
G protein coupled receptors (GPCR) are seven-transmembrane receptors, which 
constitute the largest, most ubiquitous and most versatile family of membrane 
receptors (Pierce, Premont et al. 2002). Analysis of the human genome reveals the 
possibility of 865 different GPCR sequences (Milligan 2006). Some estimate that the 
number could surpass 1000 (Brauner-Osborne, Wellendorph et al. 2007). GPCRs are 
membrane proteins that activate intracellular signaling cascades and undergo 
endocytosis, recycling, or degradation upon stimulation (Fig. 1.1) (Lee, Lynch et al. 
2000).  
 
Fig. 1.1 General scheme of GPCR signaling. The GPCR signaling comprises three parts: a seven-
transmembrane spanning receptor; a heterotrimeric G protein (figures next to each subunit indicate 
the number of variants that have been identified); and an effector, such as an enzyme or ion channel. 
(Adopted from Rockman and Kostenis et al.) (Rockman, Koch et al. 2002; Kostenis, Waelbroeck et al. 
2005). 
 
GPCRs are involved in the primary mechanism used by virtually all eukaryotic cells to 
receive, interprete and respond to a wide range of structurally and chemically diverse 
extracellular stimuli (Kostenis, Waelbroeck et al. 2005). Thus it is not surprising that 
they are also the most common (50 %) target of the therapeutic drugs (Pierce, 
Premont et al. 2002; Razvi 2005). They are studied using radioactively labeled 
receptor-specific-ligands, cell culture expression of these receptors (Richards and 
van Giersbergen 1995) or by analyzing downstream processes of receptor activation, 
such as reporter genes (Moro, Ideta et al. 1999; Liu and Wu 2004), GTP-γ-S (Moore, 
Xiao et al. 2000; Selley, Rorrer et al. 2001; Bidlack and Parkhill 2004), mitogen-
activated protein kinase (MAPK) (Leroy, Missotten et al. 2007) and cyclic AMP 
(cAMP) assays (Howlett, Qualy et al. 1986; Childers and Deadwyler 1996; 
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Mukhopadhyay, Das et al. 2006). Transgenic knock-in (Mihara, Smit et al. 2005; 
Scherrer, Tryoen-Toth et al. 2006) as well as knock-out models (Zimmer, Zimmer et 
al. 1999; Buckley, McCoy et al. 2000) allowed an alternative approach to study the 
vital roles of these proteins in in vivo systems.  
Cannabinoid receptors also belong to the family of GPCRs, defined as those that 
respond to cannabinoid drugs, such as Δ9-tetrahydrocannabinol (Δ9-THC) derived 
from plant Cannabis sativa and its biologically active synthetic analogues. 
 
1.1 Cannabinoids and their receptors 
The term cannabinoid was originally used to describe the family of approximately 
sixty, 21-carbon structures present within the preparations of plant cannabis sativa 
(Little, Compton et al. 1989; Howlett, Champion et al. 1990). Of these, the most 
significant in terms of both quantity and psychoactive efficacy is Δ9-THC (Fig. 1.2). 
 
Fig. 1.2 Chemical structure of Δ9-tetrahydrocannabinol: Structure of most studied psychoactive 
compound from plant Cannabis sativa, Δ9-THC. 
Recently the term ‘cannabinoid’ has been used to describe any compound that has 
activity at the cannabis receptors including synthetic and endogenous compounds 
(IUPHAR database). In 1992, the first endogenous compound was identified as 
arachidonoylethanolamide (AEA) and named anandamide, a name derived from the 
Sanskrit word ´anand´ for bliss and amide (Devane, Hanus et al. 1992) (Fig.1.3). It 
shows affinity for both centrally expressed cannabinoid receptor (CB1) and 
peripherally expressed (CB2) receptors and acts as a partial agonist for both. AEA 
shows Ki of 89 nM and 371 nM at CB1 and CB2 receptors respectively. Another 
endocannabinoid, 2-arachidonylglycerol (2-AG), binds also to both CB1 and CB2 
receptors (Fig. 1.3). Unlike AEA, 2-AG acts as a full and potent agonist Ki values 472 
nM and 1400 nM, respectively (Felder, Joyce et al. 1995; Mechoulam, Ben-Shabat et 
al. 1995; Showalter, Compton et al. 1996). Both endocannabinoids AEA and 2-AG 
are derived from the essential fatty acid arachidonic acid and are found in nearly all 
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tissues in a wide range of animals (Di Marzo 1998). For example, 2-AG levels (5.4 ± 
0.6 nmol/g) in hippocampus of wild type male mice were found to be about 1000 fold 
higher than AEA (51.1± 10.2 pmol/g) (Di Marzo, Breivogel et al. 2000). 
 
 
Fig. 1.3 Chemical structure of endocannabinoids: Chemical structure of two endocannabinoids, 
arachidonylethanolamide (AEA) and arachidonylglycerol (2-AG). 
Synthetic agonists that bind to cannabinoid receptors include cannabinoid 
compounds such as Δ9-THC-like ABC tricyclic cannabinoid analogues, typified by 
HU-210 (Johnson 1986) and desacetyllevonantradol (Pacheco, Childers et al. 1991; 
D'Ambra, Estep et al. 1992); synthetic AC bicyclic and ACD tricyclic cannabinoid 
analogues, typified by CP55,940, and CP55,244 (Devane, Hanus et al. 1992; Fride 
and Mechoulam 1993), and aminoalkylindole compounds, typified by WIN 55,212-2 
(Mechoulam, Ben-Shabat et al. 1995; Sugiura, Kondo et al. 1995). 
Cannabinoid crude preparations were reported to be used since 2000 B.C. in China 
for medicinal purposes (Mathre 1997). However, recent clinical trials of cannabinoids 
for multiple sclerosis (Wade, Makela et al. 2006; Collin, Davies et al. 2007), pain 
(Pinsger, Schimetta et al. 2006) have been the subject of controversy. Primarily, this 
has been the result of an association with a ‘drug of abuse’, by moral, cultural beliefs 
as well as the lack of enough scientific evidence for their beneficial effects (Mandavilli 
2003).   
 
1.2 Cannabinoid receptors 
 
1.2.1 Cannabinoid receptor 1 
CB1 receptor has been first cloned from rat (Matsuda, Lolait et al. 1990), mouse 
(Chakrabarti, Onaivi et al. 1995) and human (Gerard, Mollereau et al. 1990) tissues. 
These receptors show 97-99% amino acid sequence identity across species. The 
CB1 receptor mRNA and protein are found primarily in central nervous system (CNS) 
(Herkenham, Lynn et al. 1990; Jansen, Haycock et al. 1992; Mailleux, Parmentier et 
al. 1992). It is particularly prevalent in basal ganglia, hippocampus, cerebellum and 
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cerebral cortex (Pettit, Harrison et al. 1998; Tsou, Brown et al. 1998). It is also shown 
to be present in some non-neuronal cells and tissues, for example leukocytes, testis 
(Mailleux, Parmentier et al. 1992; Pertwee 1997; Howlett, Barth et al. 2002) and bone 
cells (Idris, van 't Hof et al. 2005; Tam, Ofek et al. 2006).  
Like most of the GPCRs, the coding sequence of the CB1 receptor is encoded by a 
single exon (for example, the human gene sequence Genebank accession U73304). 
However, an alternatively spliced form (CB1A) of the human receptor has been 
reported in which a 167 base portion of this exon is spliced out leading to the 
substitution of a different 28 residue sequence for the first 90 amino acids (Shire, 
Carillon et al. 1995).  
Therapeutically beneficial effects of CB1 receptor in nervous system in responses to 
Δ9-THC and other cannabinoid receptor agonists include analgesia (Ledent, Valverde 
et al. 1999; Zimmer, Zimmer et al. 1999), attenuation of nausea and vomiting in 
cancer chemotherapy (Niiranen and Mattson 1987; Grunberg 1989; Meiri, Jhangiani 
et al. 2007), appetite stimulation (Mattes, Engelman et al. 1994; Beal and Flynn 
1995; Koch 2001), and decreased intestinal motility (Izzo and Coutts 2005; Carai, 
Colombo et al. 2006). Side effects also accompanying these therapeutic responses 
include alterations in cognition and memory (Bilkei-Gorzo, Racz et al. 2005; 
Rodriguez de Fonseca, Del Arco et al. 2005), dysphoria/euphoria and sedation 
(Purnell and Gregg 1975; Lukas, Mendelson et al. 1995).  
CB1 receptors are coupled to pertussis toxin (PTX)-sensitive Gi/o proteins to inhibit 
adenylate cyclase activity (Howlett, Qualy et al. 1986; Pacheco, Childers et al. 1991). 
They regulate L-, N- and P- or Q-type Ca2+ channels (Mackie and Hille 1992; 
Twitchell, Brown et al. 1997; Gebremedhin, Lange et al. 1999) and G protein-
regulated, inwardly rectifying K+ channels (Mackie, Lai et al. 1995). They are also 
shown to initiate intracellular Ca2+ transients (Sugiura, Kodaka et al. 1996), stimulate 
MAPK (Sugiura, Kodaka et al. 1996) and induce immediate early gene expression 
(Bouaboula, Bourrie et al. 1995). 
 
1.2.2 Cannabinoid receptor 2 
The second cannabinoid receptor, CB2, was cloned from a human leukemia HL60 
library (Munro, Thomas et al. 1993). It exhibited 68% homology to the CB1 receptor. 
The mouse (Shire, Calandra et al. 1996) and rat CB2 (Griffin, Tao et al. 2000) 
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receptors exhibit 82% and 81% sequence identity to the human CB2 receptor 
respectively.  
CB2 receptor mRNA was found primarily in immune tissue. It can be found in human 
spleen (Galiegue, Mary et al. 1995; Schatz, Lee et al. 1997), tonsils (Carayon, 
Marchand et al. 1998), bone marrow (Ponti, Rubino et al. 2001; Lu, Newton et al. 
2006; Scutt and Williamson 2007), pancreas (Klein, Newton et al. 2001), splenic 
macrophage / monocyte preparations (Munro, Thomas et al. 1993; Carlisle, 
Marciano-Cabral et al. 2002; Carrier, Kearn et al. 2004), peripheral blood leukocytes 
(Bouaboula, Rinaldi et al. 1993), skin (Casanova, Blazquez et al. 2003; Stander, 
Schmelz et al. 2005) and in a variety of cultured immune cell models including the 
myeloid cell line U937 (Bari, Spagnuolo et al. 2006; Matsumoto, Hatanaka et al. 
2006) and undifferentiated and differentiated granulocyte-like or macrophage-like 
HL60 cells (Das, Paria et al. 1995; Facci, Dal Toso et al. 1995; Gokoh, Kishimoto et 
al. 2005) and bone cells (Ofek, Karsak et al. 2006). Certain tumors, especially 
gliomas, express CB2 receptors (Galve-Roperh, Sanchez et al. 2000).  
Signal transduction by the CB2 receptor includes PTX-sensitive inhibition of cAMP 
production in transfected host CHO cells (Felder, Joyce et al. 1995; Slipetz, O'Neill et 
al. 1995; Showalter, Compton et al. 1996; Griffin, Tao et al. 2000), MAP kinase 
activation and immediate early gene expression (Bouaboula, Poinot-Chazel et al. 
1996). They modulate migration of several cell types (Sugiura, Kondo et al. 1995; 
Jorda, Lowenberg et al. 2003), proliferation of different type of cells for example 
immune cells like B cells (Derocq, Segui et al. 1995), T cells (Klein, Newton et al. 
1985), splenocytes (Steffens, Veillard et al. 2005) and in bone cells like osteoblasts 
(Ofek, Karsak et al. 2006). Guzman and coworkers have shown that Δ9-
tetrahydrocannabinol and WIN-55,212-2, two non-selective cannabinoid agonists, 
induce the regression or eradication of malignant brain tumors in rats and mice 
(Juan-Pico, Fuentes et al. 2006). The rat glioma C6 expresses the CB2 receptor and, 
on the basis of studies with CB1 and CB2 selective antagonists, it has been 
proposed that activation of either of the two receptors may trigger apoptosis (Galve-
Roperh, Sanchez et al. 2000; Sanchez, de Ceballos et al. 2001). Intially, no 
modulation of ion channels or alterations of intracellular Ca2+ were observed in host 
cells expressing CB2 receptors (Felder, Joyce et al. 1995; Slipetz, O'Neill et al. 
1995). However, recently the endocannabinoid 2-arachidonylglycerol is shown to 
regulate Ca2+ signals in β-cells and as a consequence, it is shown to decrease insulin 
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secretion through CB2 receptors (Zoratti, Kipmen-Korgun et al. 2003; Juan-Pico, 
Fuentes et al. 2006) as well as in calf pulmonary endothelial cells CB2 receptors are 
shown to initiate Ca2+ signaling linked with phospholipase C (Zoratti, Kipmen-Korgun 
et al. 2003). 
 
1.2.3 Novel cannabinoid receptor, GPR55 
Recent studies indicate that the human orphan GPCR, GPR55 (Sawzdargo, Nguyen 
et al. 1999) which is extensively expressed in brain, is the novel cannabinoid receptor 
(Johns, Behm et al. 2007; Ryberg, Larsson et al. 2007). Cannabinoid ligand 
CP55,940 as well as endocannabinoids such as anandamide and virodhamine 
activate GTP-γ-S binding via this receptor (Baker, Pryce et al. 2006). It also binds to 
ligands such as cannabidiol and abnormal cannabidiol, which exhibit no CB1 or CB2 
activity and are believed to function at a novel cannabinoid receptor (Johns, Behm et 
al. 2007; Ryberg, Larsson et al. 2007). GPR55 couples to Gα-13 and can mediate 
activation of rhoA, cdc42 and rac1. Lysophosphatidic acid and sphingosine 1-
phosphate also induced phosphorylation of the MAPK in GPR55-expressing cells, 
thus it is also termed as a lysophosphatidylinositol receptor (Oka, Nakajima et al. 
2007). Various types of other lysolipids as well as the cannabinoid receptor ligands 
did not induce phosphorylation of the extracellular signal-regulated kinase.  
The development of selective agonists or antagonists for this novel receptor will 
further aid to understand the functional relevance of this receptor. 
 
1.2.4 Non cannabinoid receptor mediated effects 
Endocannabinoid compounds have also demonstrated a number of biological 
activities (Bouaboula, Poinot-Chazel et al. 1996) that are not considered to be 
mediated via CB1 or CB2 receptors. For example, vasodilation by AEA in the 
endothelial cell (Nazzaro, Manzari et al. 1999) and nervous tissue (Zygmunt, 
Petersson et al. 1999). This might be due to the metabolized products of arachidonic 
acid such as prostacyclin, epoxyeicosatrienoic acids, or due to the action of AEA on 
vanilloid VR1 receptors. Studies with atypical agonists have also shown non CB1 or 
CB2 dependent change in blood pressure (Adams, Earnhardt et al. 1977) and 
vasodialation (Jarai, Wagner et al. 1999; Wagner, Varga et al. 1999; Offertaler, Mo et 
al. 2003; Begg, Pacher et al. 2005). These effects were thought to be mediated by an 
unknown cannabinoid receptor. However, recent study with novel GPR55 receptor 
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knock-out mice, showed no significant difference in blood pressure and vasodialation 
compared to the wild type mice (Johns, Behm et al. 2007). 
Studies suggest that in spleen, brain and gut, 2-AG is accompanied by several 2-
acyl-glycerol esters, mainly 2-linoleoylglycerol (2-LinoG) and 2-palmitoylglycerol (2-
PalmG) (Ben-Shabat, Fride et al. 1998; De Petrocellis, Bisogno et al. 2002). These 
two esters do not bind to the cannabinoid receptors, nor do they inhibit adenylate 
cyclase (Di Marzo 1998; Lambert and Di Marzo 1999); however, they significantly 
potentiate the apparent binding of 2-AG to cannabinoid receptors and their ability to 
inhibit adenylate cyclase. In mice these esters have been shown to significantly 
potentiate 2-AG induced motor behavior inhibition, ring immobility, hot plate 
analgesia and hypothermia. Thus indicating that the biological activity of 2-AG can be 
increased by related endogenous 2-acyl-glycerols, which alone do not show any 
significant activity. This effect is termed as 'Entourage effect'. These 2-acylglycerol 
derivatives also bind to vanilloid receptor and exert entourage effects (Smart, 
Jonsson et al. 2002).  
 
1.3 The endocannabinoid system 
The endocannabinoid system consists of enzymes involved in cannabinoid 
biosynthesis (Bradley 1987; Di Marzo, Fontana et al. 1994), degradation (Cravatt, 
Giang et al. 1996) and release (Di Marzo, Fontana et al. 1994; Cadas, Gaillet et al. 
1996), as well as specific endocannabinoid transporters (Brozoski, Dean et al. 2005) 
(Fig 1.4) (Di Marzo 1998; Rodriguez de Fonseca, Del Arco et al. 2005; Bermudez-
Siva, Serrano et al. 2006). For example, AEA is synthesized by N-
arachidonylphosphatidylethanolamine (N-ArPE), which is believed to originate from 
the transfer of arachidonic acid from the sn-1 position of 1,2–sn–di-
arachidonylphosphatidylcholine to phosphatidylethanolamine catalyzed by a Ca2+-
dependent N-acyltransacylase (NAT) (Basavarajappa 2007). N-ArPE is then cleaved 
by an N-acylphosphatidylethanolamine (NAPE)-specific phospholipase D (PLD) 
(NAPE-PLD) (Natarajan, Reddy et al. 1981; Schmid, Reddy et al. 1983; Bradley 
1987; Di Marzo, Fontana et al. 1994), which releases AEA and phosphatidic acid. 
AEA is degraded by a well-characterized enzyme, the fatty acid amide hydrolase 
(FAAH)(Cravatt, Giang et al. 1996). Phospholipase C (PLC)-mediated hydrolysis of 
membrane phospholipids may produce diacylglycerol (DAG), which may be 
subsequently converted to 2-AG by diacylglcerol lipase (DAGL) activity (Prescott and 
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Majerus 1983; Sugiura, Kondo et al. 1995). Alternatively, the formation of DAG 
involves the hydrolysis of phosphatidic acid through Mg2+ and Ca2+-dependent 
phosphohydrolase activity (Bisogno, Melck et al. 1999; Carrier, Kearn et al. 2004). 2-
AG is degraded by the monoacylglycerol lipase (Dinh, Carpenter et al. 2002).  
 
Fig. 1.4 Schematic diagram of endocannabinoid system: Scheme above represents the 
endocannabinoid system, consisting of enzymes involved in synthesis, degradation and release as 
well as specific endocannabinoid transporters. Adopted from Baker et al. (Baker, Pryce et al. 2003). 
 
1.3.1 Transgenic approach to study the endocannabinoid system 
To study this system transgenic approaches have been undertaken, where specific 
enzymes or receptors have been knocked out. We and other researchers have used 
a genetic approach and generated mice with the targeted deletions in the 
cannabinoid receptor genes CB1 (Ledent, Valverde et al. 1999; Zimmer, Zimmer et 
al. 1999; Marsicano, Wotjak et al. 2002; Robbe, Kopf et al. 2002), CB2 (Buckley, 
McCoy et al. 2000) and  GPR55 (Johns, Behm et al. 2007). Studies using CB1 
knock-out mice have demonstrated that this receptor participates in the control of 
several behavioral responses including locomotion, and anxiety like states (Zimmer, 
Zimmer et al. 1999), cognitive functions such as memory and learning processes 
(Bilkei-Gorzo, Racz et al. 2005), cardiovascular responses (Jarai, Wagner et al. 
2000), modulator of the rewarding and addictive properties of other drugs of abuse 
(Ledent, Valverde et al. 1999; Martin, Ledent et al. 2000; Cossu, Ledent et al. 2001) 
and feeding (Wiley, Burston et al. 2005). 
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The CB2 knock-out model has been successfully used to reveal cannabinoid-induced 
inhibition of helper T cell activation in macrophages (Buckley, McCoy et al. 2000), the 
antifibrogenic role of the CB2 receptor in the liver injury (Julien, Grenard et al. 2005), 
in formation of B and T cell subsets (Ziring, Wei et al. 2006), in regulation of bone 
mass (Ofek, Karsak et al. 2006), in lymphocyte proliferation and cytokine secretion 
and macrophage phagocytic activity (Buckley, Burbridge et al. 2006). Activation of 
the CB2 receptor has been also shown to have anti-artherosclerotic properties in 
mouse model (Steffens, Veillard et al. 2005).  
We have also generated the cannabinoid receptor double knock-out mice. This 
model had helped to understand residual cannabinoid effects of cannabinoids like 2-
AG, on interferon-gamma suppression in phorbol ester/ionomycin activated 
splenocytes (Kaplan, Ouyang et al. 2005), Δ9- THC and cannabinol on induction of 
calcitonin gene-related peptide (Zygmunt, Andersson et al. 2002), and of cannabinol 
on induction of hypotension in mice (Jarai, Wagner et al. 1999).   
 
1.4 Aim  
I wanted to investigate severe ulcerations phenotype of CB1-CB2 receptors deficient 
mice. I also aimed to generate a novel knock-in mouse line, with functional 
fluorescent tagged CB2 receptors. This will help to study the exact localization and 
dynamics of the receptors in an in vivo system. For this I wanted to intially establish 
an in vitro overexpression system to characterize the functionality of fused CB2 
receptors.  
 
In context of this work the following aims were set: 
 
●   To study wound healing in the CB1-CB2 knock-out mice 
●  Generation of Knock-in mice, with fluorescent tagged receptor, GFP- coupled 
(and CFP coupled) CB2-receptor 
● Generation of an in vitro system having CB2 fusion protein 
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2 Materials 
All chemicals used had the quality p.a. (per analysis) from Invitrogen (Karlsruhe), 
Sigma (Taufkirchen) or AppliChem (Darmstadt) unless mentioned otherwise.  
2.1 Instruments 
-80 °C Freezer   Heraeus Instruments GmbH (Hanau) 
Autoclave    Varioclave 25T, HP Labortechnic AG   
     (Oberschleißheim) 
Bacterial shaker   Innova 4200 Incubator shaker, New Brunswick 
 Scientific (USA) 
BD LSR II FACS   BD LSR II Flowcytometer BD (USA) 
Bioanalyzer    Agilent 2100 Bioanlyzer, Agilent (Waltbronn) 
CCD camera    KY-F75U, JVC (Japan) 
Cell incubator   CB 210, Binder GmbH (Tuttlingen) 
Centrifuge   Biofuge pico, Heraeus Instruments GmbH (Hanau) 
Centrifuge    Biofuge stratos, Heraeus Instruments GmbH  
     (Hanau) 
Centrifuge  Biofuge fresco, Heraeus Instruments GmbH  
  (Hanau) 
Chemical balance   BP 121 S, Sartorius AG (Goettingen) 
Confocal microscope  Olympus (USA) 
Cryopreservator   Linde systems (Muenchen) 
Cryostat    CM 3050 S, Leica GmbH (Nussloch)   
Developing machine  X-OMAT 1000, Kodak GmbH (Stuttgart) 
Digital gel documentation  ChemiDoc System, Bio-Rad Laboratories GmbH 
     (Muenchen) 
Electroporator   Gene pulser II, Bio-Rad Laboratories GmbH  
     (Muenchen) 
Electrophoresis chamber  Bio-Rad Laboratories GmbH (Muenchen) 
Engineer's micrometer   Oditest, Fa. Kroeplin (Schluechtern) 
Fluorescence macroscope     Leica MZ16F, Leica microsystems (Nussloch) 
Fluorescence microscope      Axiovert 40 CFL, Carl Zeiss AG (Jena) 
Fluorescence microscope   Axioplan 2, Carl Zeiss AG (Jena) 
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Heating block   HLC (Bovenden) 
Homogenizer   T8 Ultra-turrax, IKA GmbH (Staufen) 
Hybridization incubator   HB 1000, UVP Laboratory (USA) 
Magnetic stirrer   MR 3001 K, Heidolph, Fischer (Duesseldorf) 
Microplate reader   DYNEX Technologies GmbH (Berlin) 
Millipore unit    Millipak express 20, Millipore (USA)  
Mini-Protean® 3 Cell   Bio-Rad Laboratories GmbH (Muenchen) 
Neubauer cell chamber  Bright–Line, Hausser Scientific (USA) 
PCR iCycler    iCycler, Bio-Rad Laboratories GmbH (Muenchen) 
pH meter    inoLab, WTW GmbH (Weilheim) 
Powerpac 300    Bio-Rad Laboratories GmbH (Muenchen) 
Shaker    Combi shaker KL2, Edmund Buehler GmbH  
     (Hechingen) 
Spectro photometer  91-ND-1000 UV/Vis, Nanodrop (USA) 
Sterile bank    Herasafe KS15, Heraeus Instruments GmbH  
     (Hanau) 
Ultracentrifuge   Sorvall Evolution RC, Kendro (USA). 
Ultrasonic homogenizer  Sonoplus, Bandelin (Berlin)  
UV crosslinker   UV Stratalinker 2400, Stratagene (USA) 
UV handlamp   UVM-57, Upland (USA)  
Vacuume blotter   Basic Unit (1655003), Bio-Rad Laboratories GmbH 
     (Muenchen) 
Vacuume pump   Bio-Rad Laboratories GmbH (Muenchen) 
Vortexer    Vortex-Genie 2, Scientific Industries (USA) 
2.2 Reagents and Chemicals 
Agarose  Invitrogen GmbH (Karlsruhe) 
AM 630   Biotrend GmbH (Koeln) 
Aqua/polymount Polyscience Europe GmbH (Eppelheim) 
Blocking reagent  Roche Diagnostics GmbH (Mannheim) 
Bovine serum albumin (fraction V)  Sigma GmbH (Taufkirchen) 
CDP–Star  New England BioLabs GmbH (Frankfurt) 
Complete mini protease inhibitor cocktail  Roche Diagnostics GmbH (Mannheim) 
Dulbecco´s MEM  Gibco / Invitrogen GmbH (Karlsruhe) 
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ECL reagent Perbio GmbH (Bonn) 
F12 + glutamax-I (Hams)  Gibco / Invitrogen GmbH (Karlsruhe) 
Fetal calf serum   Gibco / Invitrogen GmbH (Karlsruhe) 
G418™   Gibco / Invitrogen GmbH (Karlsruhe) 
HBSS   Gibco / Invitrogen GmbH (Karlsruhe) 
Lipofectamine 2000  Invitrogen GmbH (Karlsruhe) 
MOPS  AppliChem GmbH (Darmstadt) 
Non essential aminoacids    Invitrogen GmbH (Karlsruhe) 
Penicillin/Streptomycin   Gibco / Invitrogen GmbH (Karlsruhe) 
RNase-Off  AppliChem GmbH (Karlsruhe) 
RPMI 1640   PAA GmbH (Pasching)  
Salmon sperm DNA  Invitrogen GmbH (Karlsruhe) 
Sodium pyruvate (100mM)   Invitrogen GmbH (Karlsruhe) 
Transferrin conjugate (Texasred)  Molecular probes, Invitrogen GmbH  
  (Karlsruhe) 
TRIzol®reagent   Invitrogen GmbH (Karlsruhe) 
Trypsin EDTA (0.25% / 0.02%)  Gibco / Invitrogen GmbH (Karlsruhe) 
Ultrapure distilled water   Gibco / Invitrogen GmbH (Karlsruhe) 
Win 55,212-2 mesylate  Tocris Bioscience (USA) 
2.3 Enzymes 
Accutaq LA polymerase     Sigma Chemicals GmbH (Deisenhofen) 
Alkaline phosphatase     New England BioLabs GmbH (Frankfurt) 
DNase I       Applera GmbH (Darmstadt) 
Hotstart DNA polymerase     Qiagen GmbH (Hilden) 
Proteinase K       Invitrogen GmbH (Karlsruhe) 
Recombinant Pfx DNA  polymerase   Invitrogen GmbH (Karlsruhe) 
Restriction endonucleases    New England BioLabs GmbH (Frankfurt) 
Superscript II RT (200 U)     Invitrogen GmbH (Karlsruhe) 
T4 DNA Ligase      Invitrogen GmbH (Karlsruhe) 
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2.4 Consumables   
Bacterial culture tubes            Sarstedt (Nuembrecht) 
24 and 96 well plates            Greiner Labortechnik (Solingen) 
Autoradiography film            GE Healthcare Europe GmbH (Muenchen) 
Cell culture plates             Greiner Labortechnik (Solingen) 
Cryo Tube™     Nunc (Wiesbaden) 
Eppendorf reaction tubes            Eppendorf–Netheler-Hinz GmbH  
            (Hamburg)  
Falcon 2052            Becton & Dickinson (Aalst, Belgien) 
Needle (sterile)            Microlance 3 (Fraga, Spanien) 
Nylon Transfer membrane            Schleicher & Schuell (Dassel) 
PCR tubes            Sarstedt (Nuembrecht) 
Petri dish (bacterial)                   Greiner Labortechnik (Solingen) 
pH strips            Merck (Darmstadt) 
Protran Cellulose nitrate            Schleicher & Schuell (Dassel) 
SuperFrost®Plus slides            Menzel GmbH & Co. KG (Braunschweig)  
Whatman paper             Schleicher & Schuell GmbH (Dassel) 
2.5 Molecular weight standards 
 
The following molecular weight standards were used for agarose gels and Southern 
blots. 
Tab. 2.1: Molecular weight standards for Southern blot 
Molecular weight standard Fragment sizes  [bp] 
DNA 100bp ladder  
(Invitrogen GmbH, Karlsruhe) 
2,072; 1,500; 1,400; 1,300; 1,200; 1,100; 1,000; 
900; 800; 700; 600; 500; 400; 300; 200; 100 
DNA 1kb ladder  
(Invitrogen GmbH, Karlsruhe) 
12,216; 11,198; 10,180; 9,162; 8,144; 7,126; 
6,108; 5,090; 4,072; 3,054; 2,036; 1,636; 1,018; 
506; 496; 344; 298; 220; 201; 154; 134; 75 
DNA–Marker II, DIG–coupled  
(Roche Diagnostics GmbH Mannheim) 
23,130; 9,416; 6,557; 4,361; 2,322; 2,027; 564; 
125 
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The following molecular weight standards were used on polyacrylamide gels in 
Western blots. 
Tab. 2.2: Molecular weight standards for Western blot 
Molecular weight standard Calibrated molecular weight  [kD] 
Prestained SDS- PAGE standards   
(Bio-Rad, Karlsruhe) 
220; 120; 100; 80; 60; 50; 40; 30; 20 
Magic mark™ Western standard  
(Invitrogen GmbH, Karlsruhe) 
201; 115; 96; 52; 38; 29; 20; 7 
2.6 Oligonucleotides 
All oligonucleotide primers were synthesized by Metabion (Martinsried) or Invitrogen 
(Karlsruhe). 
Tab. 2.3: Sequencing primers 
 
Name 
Sense + 
antisense - 
Primer sequence 5' - 3' 
CFP KI Geno1F + TCGGACCTGAGGGGAAAGAAGA 
BGH rev - TAGAAGGCACAGTCGAGG 
Dsred Mono F + ATGGTGCGCTCCTCCAAGAA 
Dsred Mono R - CTACAGGAACAGGTGGTGGC 
Dsred1-N + GTACTGGAACTGGGGGGACAG 
EGFP-N  - CGTCGCCGTCCAGCTCGACCAG 
EGFP-N 1 rück + GTAATACGACTCACTATAGGGC 
EXFP-1 hin + CAGCACGACTTCTTCAAGTC 
EXFP-1 rück - CAGCTCGATGCGGTTCACCAG 
CFP KI Geno WT 3R - CTACAGCCACAGAGGATGAAG 
CFP KI GFP 1R - CCTCGGCGCGGGTCTTGTA 
mCB2 2 hin + CACCGGCATGTAGCCACCTTGG 
mCB2 2 rück - AGCGTGATCTTCGCCTGCAACTTTG 
mCB2 4 rück - CCAAGGTGGCTACATGCCGGTG 
mCB2 5 hin + AGCCGTGATCTTCGCCTGCAACTTTG 
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Name 
Sense + 
antisense - 
Primer sequence 5' - 3' 
mCB2-1 rück - CAAAGTTGCAGGCGAAGATCACGCT 
Neo 1 rück - GATATTCGGCAAGCAGGCATC 
Neo 1hin + GAGGCTATTCGGCTATGACTG 
New LOX P2 + ATATTGCTGAAGCTTGGCGGC 
PPNT-loxP1 hin + GCGGCCGCTCGAAGTTAACG 
PPNT-neo 1 hin + CAGCTGTGCTCGACGTTGTCAC 
PPNT-neo 1 rück - GAGTACGTGCTGGCTCGATGC 
SP6-Primer + ATTTAGGTGACACTATAG 
T7-Primer + TAATACGACTCACTATAGGG 
Tab. 2.4 Knock-in construct cloning primers 
Name 
Sense + 
antisense - 
Primer sequence 5' - 3' 
Short  arm 
mCB2-exon  3 hin   Pac + TTAATTAAGGTGCTGTGCTTGAGCTACG  
mCB2-exon rück Gly,AgeI  - ACCGGTCCGGTGGTTTTCACATCAGCCTC  
Long arm 
mCB2-3'UTR 1rück KpnI - GGTACCCTCGACCACAGCGTGTGCATG 
mCB2-3'UTR hin Xma + CCCGGGTAGGAGCCAGGATCCAGAACTC  
Tab. 2.5: DIG probe primers 
Name 
Sense + 
antisense - 
Primer sequence 5' - 3' 
mCB2-5'sonde 5hin + CAGGAGCAGCAGTCTGCAGA 
mCB2-5'sonde 5rück - GTGTATTTCCACATCCCTATG 
eGFP hin + CAGCACGACTTCTTCAAGTC 
eGFP rück - CTGCTTGTCGGCCATGATA 
Neo hin + GAGGCTATTCGGCTATGACTG 
Neo rück - GATATTCGGCAAGCAGGCATC 
  Materials 
 
                                                  16
Tab. 2.6: Expression vectors cloning primers  
Name 
Sense + 
antisense - 
Primer sequence 5' - 3' 
Fusion construct   
D_mCB2_KZ_F + CACCATGGAGGGATGCCGGGAGAC 
GFP Stop Not1 R - GCGGCCGCTTTACTTGTACATGT 
Control construct   
mCB2-exon stop  rück - CTAGGTGGTTTTCACATCAGCCTC 
 
Tab. 2.7: RT–PCR Primer 
Name Sense + 
antisense -
Primer sequence 5' - 3' 
CFP KI Geno1F + TCGGACCTGAGGGGAAAGAAGA 
CFP KI Geno WT 3R - CTACAGCCACAGAGGATGAAG 
CFP KI Geno GFP 1R - CCTCGGCGCGGGTCTTGTA 
ß actin F + AGAGGGAAATCGTGCGTGAC 
ß actin R - CAATAGTGATGACCTGGCCGT 
2.7 Antibody and Antiserum 
The following antibodies were used. The source and the used dilutions are indicated. 
 
Tab. 2.8:  Antibodies 
 
Antibody Description Source 
Primary Antibody 
p44/42 MAP Kinase 
Antibody #9102 
Detects total p44/42 MAP-Kinase 
Cell Signaling Technology, WB 1:1,000 dilution 
Rabbit 
Phospho-p44/42 MAP 
Kinase (Thr202/Tyr204) 
Antibody #9101 
Detects phospho-p44/42 MAP-Kinase forms, 
Cell Signaling Technology, WB 1:1,000 dilution 
Rabbit 
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Antibody Description Source 
AntiGFP antibody 
# Ab290 
Detects GFP protein 
Abcam, WB 1:5,000 dilution 
Rabbit 
Anti-GFP 
Obtained from Prof. Magin 
(University of Bonn) 
Detects GFP protein 
Hybridoma generated by Prof. Noegel 
(Inst. for Biochem. I, Cologne), WB 1:5,000 dilution 
Mouse 
 
Anti ß-actin 
# A1978 
 
Detects ß-actin, 
SigmaAldrich, WB 1:12,000 dilution 
Mouse 
∝- Giantin 
Obtained from Prof. Walter 
(University of Bonn) 
Detects Giantin protein. 
Generated by Linstedt et. al 
ICC 1:500 dilution 
Rabbit 
LAMP I 
# 121603 
Detects LAMP I protein, 
BioLegends, ICC 1:500 dilution 
Mouse 
LIMP II 
# sc25869 
Detects LIMPII protein, 
Santacruz Biotechnology Inc., ICC 1:500 dilution 
 
Goat 
 
Calnexin 
# sc11397 
Detects Calnexin protein, 
Santacruz Biotechnology Inc., ICC 1:500 dilution 
Rabbit 
CB2 antibody 
# 101550 
Detects Cannabinoid receptor 2 
Cayman chemicals, ICC 1:500 dilution, WB 1:2,000 
Rabbit 
 
Secondary antibody 
Anti-Rabbit Cy 3 
# 111-165-003 
 
Detects Rabbit IgG, Cy3 coupled; red emission; 
Dianova, ICC dilution 1:500 
Goat 
Anti-Goat Cy 3 
# 305-165-003 
 
Detects Goat IgG, Cy3 coupled; red emission; 
Dianova, ICC dilution 1:500 
Rabbit 
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Antibody Description Source 
Anti-Mouse Cy 3 
# 715-165-150 
 
Detects Mouse IgG, Cy3 coupled; red emission;  
Dianova, ICC dilution 1:500 
Donkey 
Anti-Rabbit HRP 
# 111-035-144 
 
Detects Rabbit IgG, Horseradish peroxidase coupled;  
Jackson ImmunoResearch Laboratories 
Goat 
Anti-Mouse HRP 
# 315-035-006 
 
Detects Mouse IgG, Horseradish peroxidase coupled;  
Jackson ImmunoResearch Laboratories 
Rabbit 
 
2.8 Kits  
 
 
The following kits were used: 
 
• BCATM Protein assay kit, Perbio GmbH (Bonn) 
• Expand high fidelity PCR system, Roche Diagnostics GmbH (Mannheim) 
• Nucleotide removal kit, Qiagen GmbH (Hilden) 
• PCR DIG labeling mix, Roche Diagnostics GmbH (Mannheim) 
• Peqlab gel extraction kit, Peqlab GmbH (Erlangen)  
• PureLinkTM HiPure midi plasmid purification kit, Invitrogen GmbH (Karlsruhe) 
• PureLinkTM HQ mini plasmid purification kit, Invitrogen GmbH (Karlsruhe) 
• RNeasy mini kit, Nr.79654, Qiagen GmbH (Hilden) 
• SYBR® Green JumpStartTM Taq ReadyMixTM, Sigma Chemie GmbH 
(Deisenhofen) 
• TOPO TA cloning®, Invitrogen GmbH (Karlsruhe) 
• Zero Blunt® TOPO® PCR cloning, Invitrogen GmbH (Karlsruhe) 
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2.9 Plasmids 
Tab. 2.9: Description and origin of all plasmids used in this work 
Vector Description Source 
Knock-in constructs 
2.5 kb-mCB2 exon- gly/AgeI 
PCR-blunt II -TOPO  
2.5 kb short arm for homologous 
recombination 
Generated by 
Andrea Oster 
2.5 kb-mCB2 exon-gly/AgeI-
eCFP-N1 
2.5 kb short arm fused with eCFP protein for 
homologous recombination 
Generated by 
Andrea Oster 
2.5 kb-mCB2 exon- 
gly/AgeI-eGFP-N1 
2.5 kb short arm fused with eGFP protein for 
homologous recombination 
Generated during 
this work 
pPNT-M2 
pPNT-M2 vector used for homologous 
recombination 
Lab stock 
6.4 kb-mCB2-3’UTR kpnI-PCR 
XL-TOPO® 
6.4 kb long arm used for homologous 
recombination 
Generated by 
Andrea Oster 
2.5 kb-mCB2 exon-eCFP-pPNT-
M2 
Plasmid containing short arm of CB2-eCFP 
and pPNT-M2 vector 
Generated during 
this work 
2.5 kb-mCB2 exon-eGFP-pPNT-
M2 
Plasmid containing short arm CB2-eCFP and 
pPNT-M2 vector 
Generated during 
this work 
mCB2-eCFP short+long arm-
pPNT-M2 
CB2-eCFP, targeting construct containing 
short and long arms 
Generated by 
Andrea Oster 
mCB2-eGFP short+long arm-
pPNT-M2 
CB2-eCFP, targeting construct containing 
short and long arms 
Generated during 
this work 
pCR®-Blunt II-TOPO® LacZa, ccdB lethal, MCS, KanR Invitrogen 
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Vector Description Source 
EGFP-N1 
MCS, NeoR; vector for expression of 
C-terminal eGFP fusion (CMV promotor) Clontech 
ECFP-N1 
MCS, NeoR; vector for expression of 
C-terminal eCFP fusion (CMV promotor) Clontech 
Expression constructs 
pcDNA™3.1D/V5-His-TOPO® 
 
MCS, AmpR, NeoR, V5–Epitope, 6x His-Tag; 
expression vector (CMV promotor) 
Invitrogen 
pCR®II-TOPO® 
 
lacZa, MCS, AmpR, KanR; cloning, sequencing 
vector 
Invitrogen 
mCB2 exon- gly/AgeI PCR-blunt 
II -TOPO  
CB2 coding exon where stop signal was 
mutated 
Generated during 
this work 
mCB2-eCFP pcDNA™3.1 D/V5-
His-TOPO® 
CB2-eCFP construct used for expression 
analysis 
Generated during 
this work 
mCB2-eGFP- 
pcDNA™ 3.1D/V5-His-TOPO® 
CB2-eGFP construct used for expression 
analysis 
Generated during 
this work 
mCB2 * pcDNA™ 3.1 D/V5-His-
TOPO® 
CB2 control construct used for expression 
analysis 
Generated during 
this work 
DsRed-monomer-N1 Vector containing dsRed fluorescent protein Clontech 
mCB2-DsRed-monomer-N1 
CB2-dsRed construct used for expression 
analysis 
Generated during 
this work 
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2.10 DIG labeled probes 
Tab. 2.10: Description of the DIG labeled PCR probes 
 
Probe Primers used     Blot 
GFP DIG eGFP hin (+) and eGFP rück (-) Southern blot 
 
5' UTR DIG mCB2-5' sonde 5hin (+) and mCB2-5' sonde 5rück (-) Southern blot 
 
Neo DIG Neo hin (+) and Neo rück (-) Southern blot 
 
2.11 Escherichia coli (E. coli) stock  
 
These bacteria were used for the transformation of recombinant plasmids. 
DH5α (Invitrogen GmbH, Karlsruhe) F-, φ80lacZΔM15, Δ(lacZYA-argF)U169, recA1, 
endA1, hsdR17(rk-, mk+), phoA, supE44, thi-1, gyrA96, relA1 and tonA  
TOP10 (Invitrogen GmbH, Karlsruhe) F-, mcrA, Δ(mrr-hsdRMS-mcrBC), 
Φ80lacZΔM15, ΔlacX74, recA1, araD139, Δ(araleu)7697, galU, galK, rpsL, (StrR), 
endA1 and nupG.  
 
2.12 Eukaryotic cell lines 
Tab. 2.11: Description and origin of cell lines used in this work 
Cell line Description Origin /Reference 
CHO-K1 
 
Chinese hamsters ovary cell line 
 
American Type Culture 
Collection (ATCC) 
HEK-293 
 
Human embryonic kidney cell line 
 
American Type Culture 
Collection (ATCC) 
HeLa 
 
Human cervical cancer cell line 
 
American Type Culture 
Collection (ATCC) 
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2.13 Mouse strains 
The Rheinische Friedrich Wilhelms University of Bonn and the Government of NRW, 
Germany, or the local veternary authorities of Zurich, Switzerland approved all animal 
experiments. The institutional and national guidelines for the care and use of 
laboratory animals were followed. 
 
Tab. 2.12: Description and origin of all mouse strains used in this work 
Mouse strain Origin 
C57BL/6J Charles River GmbH, Sulzfeld 
CD1 Charles River GmbH, Sulzfeld 
Cnr1-/- House of experimental therapy, Bonn 
Cnr2-/- House of experimental therapy, Bonn 
Cnr1-/-/Cnr2-/- House of experimental therapy, Bonn 
 
2.14 ES cells  
Tab. 2.13: Description and origin of all mouse ES cell lines used in this work 
ES cell Origin 
R1 Embryonic stem cell line from F1 crossing between 129/Sv and 129/J mice  
MPI 2 Embryonic stem cell line from blastocytes from 129/Sv mice 
 
2.15 Growth Mediums  
2.15.1 Growth medium for E. coli  
All growth mediums were made in ultrapure milli Q water. 
Luria Bertani (LB) medium 
Bactotryptone                        1% (w/v) 
Yeast extract        0.5% (w/v) 
NaCl          0.5% (w/v) 
pH was adjusted to 7.5 with NaOH and then solution was autoclaved. 
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Luria Bertani (LB) 1.5% agar 
Bactotryptone        1% (w/v) 
Yeast extract        0.5% (w/v) 
NaCl          0.5% (w/v) 
Agar          1.5% (w/v) 
 
The pH was adjusted to 7.5 with NaOH. The solution was autoclaved, cooled to 50°C 
and the corresponding antibiotics (30 μg/ml Kanamycin, 30 μg/ml Ampicillin) were 
added. Approximately 25 ml medium were poured per petridish and allowed to 
solidify.  Plates were then packed under sterile conditions and stored at 4 °C until 
use. 
  
2.15.2 Growth medium for ES cells  
 
ES cell growth medium:  
DMEM (high glucose) 
FCS (ES-cell tested)        26% 
Non essential amino acids      1.2% 
Penicillin         3 U/l 
Streptomycin        3 U/l 
Sodium pyruvate solution       0.6% 
ß-Mercaptoethanol        0.2%  
LIF          2 ng/ml 
 
Fibroblast growth medium:  
DMEM (high glucose) 
FCS          10% 
Penicillin streptomycin mix      0.6% 
Sodium pyruvate solution       0.5% 
 
ES cell selection medium: 
DMEM (high glucose) 
FCS (ES cell tested)        26% 
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Non essential amino acids      1.2% 
Penicillin streptomycin mix      0.6% 
Sodium pyruvate solution       0.6% 
ß-Mercaptoethanol        0.2% 
LIF          2 ng/ml 
G418          170 ng/ml 
FIAU          130 nM 
 
ES cell freezing medium:  
DMEM (high glucose) 
FCS          50% 
DMSO         10% 
2.16 Solutions 
Unless otherwise mentioned, all solutions were made in ultrapure milli Q water at 
room temperature. 
 
DEPC water: 1ml DEPC solution was added to 1 l ultrapure milli Q water. The 
solution was shaked and kept in the dark overnight and next day solution was 
autoclaved.  
 
Gelatine solution:  
Gelatine          1% (w/v) 
The solution was autoclaved and then used for cell culture experiments. 
 
1x Phosphate buffered saline (PBS) Ca2+/Mg2+ free, pH 7.4: 
NaCl                    140 mM 
KCl            10 mM 
Na2HPO4              6.4 mM 
KH2PO4                        2 mM 
The solution was autoclaved and then used for cell culture experiments. 
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4% Paraformaldehyde (PFA)/PBS (w/v):  
10 g PFA were dissolved in 250 ml 1x PBS and heated to 60°C and 3 - 4 drops of 2 
M NaOH was added to clear the solution. PFA solution was cooled to 4°C before 
use. 
Mitomycin solution: 
Mitomycin C in fibroblast medium     10 μg/ml 
 
Lysis buffer for ES cells: 
Tris HCl, pH 8.0        20 mM 
NaCl          10 mM 
EDTA          10 mM 
SDS          0.5% 
Proteinase K         1 mg/ml 
 
Colchicin solution: 
Cholchicin in HBSS buffer       10 μg/ml 
 
TE buffer, pH 8:  
Tris HCl         10 mM  
EDTA          100 mM 
 
Alkaline lysis reagent for genomic DNA isolation: 
NaOH          25 mM  
EDTA          0.2 mM 
 
Neutralization reagent for genomic DNA isolation: 
Tris HCl, pH 5        40 mM 
 
Lysis buffer for protein isolations: 
MgCl2          30 mM 
NaCl           100 mM 
NP-40          5% 
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Tris HCl, pH 8         100 mM   
Lysis buffer for protein isolations (Erk-MAPK):  
Tris HCl         50 mM 
Triton X-100         1% 
NaCl          150 mM 
EGTA          1 mM 
β-glycerol phosphate        50 mM 
NaF          1 mM 
Leupeptin          10 µg/ml 
Aprotinin           10 µg/ml 
PMSF           0.5 mM   
Sodium orthovanadate        1 mM  
2.16.1 DNA gel electrophoresis 
 
6x Sample buffer:  
Glycerol         50% (v/v) 
EDTA          0.002 mM 
Bromo phenol blue        0.0025% (w/v) 
Xylene cyanol        0.0025% (w/v) 
 
 
6x Sample buffer:  
Glycerol         50% (v/v) 
EDTA          0.002 mM 
Orange G         0.0025% (w/v) 
 
TAE gel electrophoresis buffer:  
EDTA          0.5 mM 
Tris acetate         40 mM 
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2.16.2 RNA gel electrophoresis 
 
10x Formaldehyde (FA) buffer:  
EDTA          10 mM 
Sodium acetate        50 mM 
MOPS         200 mM 
Chemicals were dissolved in DEPC milli Q water and pH was adjusted to 7 with 
NaOH. 
 
1x Formaldehyde (FA) gel running buffer: 
10x Formaldehyde buffer       10% (v/v) 
Formaldehyde, 37%        2% (v/v) 
Chemicals were dissolved in DEPC milli Q water. 
 
5x RNA sample buffer:  
Bromophenol blue        0.0025% (w/v) 
EDTA          4 mM 
Formaldehyde, 37%       7.2% (v/v) 
Formamide         30.84% (v/v) 
10x Formaldehyde buffer       40% (v/v) 
Glycerol         20% (v/v) 
Chemicals were dissolved in DEPC milli Q water. 
 
2.16.3 Solutions for Southern blot 
Depurination solution: 
HCl                                             250 mM 
 
Denaturation solution: 
NaOH          500 mM 
NaCl          1.5 M 
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Neutralization solution, pH 7: 
Tris HCl         500 mM 
NaCl          1.5 M 
 
Maleic acid buffer, pH 7.5: 
Maleic acid         100 mM 
NaCl          150 mM 
 
20x SSC buffer, pH 7: 
NaCl          3 M 
Sodium citrate        300 mM 
Standard hybridization buffer for Southern blot: 
Blocking reagent        1% (w/v) 
20x SSC buffer        25% (v/v) 
N-Lauroyl sarcosine        0.1% (w/v) 
SDS          0.02% (w/v) 
 
Wash buffer 1: 
20x SSC buffer        10% (v/v) 
SDS          1% (w/v) 
 
Wash buffer 2: 
20x SSC buffer        1% (v/v) 
SDS          0.1% (w/v) 
Stock solution for blocking: 
Blocking reagent         10% (w/v) 
Reagent was dissolved in maleic acid buffer, autoclaved and stored at -20°C. 
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Blocking solution: 
Stock solution for blocking       10% (v/v) 
Maleic acid buffer        90% (v/v) 
The solution was filtered with Whatman  filters (Schleicher & Schuell). 
 
Wash buffer 3:  
0.3% Tween 20 in maleic acid buffer. 
 
Assay buffer pH 9.5: 
Tris HCl         100 mM 
NaCl          100 mM 
MgCl2          50 mM 
The pH was set with NaOH to 9.5  
 
 
2.16.4 Solutions for protein gel electrophoresis and Western blot 
 
12% Separation gel buffer: 
Tris HCl, pH 8.8        375 mM  
SDS          0.1% (w/v) 
Acrylamide         12% (w/v)  
Bisacrylamide        0.24% (w/v)  
Ammonium persulphate       0.1% (w/v)  
TEMED         0.1% (v/v) 
 
5% Stacking gel buffer: 
Tris HCl, pH 6.8        187.5 mM  
SDS          0.1% (w/v)  
Acrylamide         5% (w/v)  
Bisacrylamide        0.1% (w/v)  
Ammonium persulphate       0.1% (w/v) 
TEMED         0.1% (v/v) 
4x Protein Sample buffer: 
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Tris HCl, pH 6.8        200 mM  
SDS          8% (w/v) 
Glycerol         40% (v/v)  
Bromophenol blue        0.01% (w/v) 
1 M DTT         40% (v/v)  
 
Laemmeli gel electrophoresis buffer: 
Tris HCl         25 mM  
SDS          0.1% (w/v) 
Glycine         192 mM  
 
Transfer buffer: 
Tris HCl         25 mM  
Glycine         192 mM  
Methanol         10% (v/v) 
 
Ponceau red solution: 
Acetic acid         5% (v/v) 
Ponceau red         0.1% (w/v) 
 
Wash buffer: 
Tris  HCl         20 mM  
NaCl          140 mM  
Tween 20         0.1% (v/v) 
Immunoprecipitation buffers: 
 
STEN buffer: 
Tris, pH 7.6          150 mM  
NaCl           500 nM 
EDTA          2 mM 
Igepal          0.2%  
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STEN lysis buffer:  
Triton X-100          1% (v/v)  
Igepal          1% (v/v) 
BSA           2% (v/v)  
Chemicals were dissolved in STEN buffer. 
 
STEN NaCl: 
Tris pH 7.6         50 mM 
NaCl          500 mM 
EDTA          2 mM 
Igepal          0.2% (v/v) 
 
Protein A/G sepharose suspension (Zymed): 
100 mg/ml protein-A bound sepharose beads were washed with STEN buffer and 
resuspended in STEN buffer. Beads were blocked with 2 mg/ml BSA to avoid non-             
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3 Methods 
3.1 Molecular biological methods 
3.1.1  DNA restriction digestion 
Digestions of DNA with restriction endonucleases were performed according to the 
instructions given by the manufacturer (New England BioLabs). 
3.1.2  Dephosphorylation of DNA fragments 
Vectors that were digested with restriction endonucleases and have two compatible 
ends can self ligate. In order to minimize such ligations and to increase the cloning 
efficiency, the 5’-phosphate group of the linearized vectors was removed by an 
alkaline phosphatase from the Garnele P. borealis (New England BioLabs). 
Linearized vectors (1 µg) were treated with 1 U of shrimp alkaline phosphatase SAP 
(New England BioLabs) for 15 min at 37°C. Prior to addition of insert DNA for 
ligation, dephosphorylation reactions were terminated by heat inactivation at 65°C for 
30 min.   
3.1.3 Ligation of digested DNA fragments  
75 ng of purified linearized vector and PCR product were used in a molar ratio of 1:2 
or 1:3 respectively. Using T4 ligase (5U/µl, Invitrogen), the ligation reaction was 
carried out according to the instructions supplied by the manufacturer. The ligation 
reaction volume (5-10 µl) was used for transformation of competent E. coli. 
3.1.4 Ligation of PCR products 
PCR products were ligated with the TOPO® TA cloning kit (Invitrogen). To avoid auto 
degradation of adenosine overhangs upon longer storage intervals, freshly prepared 
PCR products were used. If blunt end producing (3´-5´ exonuclease activity, proof 
reading activity) polymerase was used, the ligation was carried out using the Zero 
Blunt® TOPO® PCR cloning kit (Invitrogen). The ligation was done according to the 
manufacturer's directions. 
3.1.5 Transformation and culture of E. coli  
The ligation product (10 µl) was mixed with 100 µl of competent E. coli (DH5 α or Top 
10) and incubated on ice for 30 min. Next the cells were heat shocked at 42°C for 40 
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s and were quickly placed on ice for 2 min. 1 ml LB or SOC medium was added and 
cells were incubated in a bacterial shaker at 37°C with for 1 h. Tubes were then 
centrifuged for 1 min at 12,000 rpm. The pellet was resuspended in 50- 200 µl of 
respective medium and cells were streaked on LB-plates with respective antibiotic. 
After 14-20 h of incubation at 37°C, colonies were chosen and kept for overnight 
cultures in 5 ml LB-growth medium with the respective antibiotic.  
3.1.6  Preparation of plasmid DNA 
3.1.6.1 Plasmid DNA isolation (mini preparation) 
For analytical purposes, 2 ml of overnight bacterial culture was used. The plasmids 
were isolated using silica columns according to manufacturer's instructions (mini kit, 
Invitrogen). 
 
       3.1.6.2 Preparative Plasmid DNA isolation (midi/maxi preparations) 
For preparative purposes, 100 ml - 500 ml of overnight bacterial culture was used. 
The plasmids were isolated with silica columns according to manufacturer's 
instructions (Midi/Maxi kit, Invitrogen). 
3.1.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to resolve DNA constructs. Agarose gels were 
casted in TAE Buffer. DNA samples were diluted in 5x loading dye before loading on 
agarose gels. One kb and 100 bp molecular weight ladders (Invitrogen) were used to 
analyze the molecular size of the DNA. Gels were run at 80-120 V in TAE buffer. 
After a run, gels were soaked in 0.5 µg/ml ethidium bromide containing TAE buffer for 
15 min. The run was documented using the Chemi Doc system (Bio-Rad). 
 
3.1.8 Isolation of DNA fragments from agarose gel 
Under UV-light desired bands were cut out from the gel using a sterile scalpel. DNA 
was extracted from the agarose using the Peqlab gel extraction kit. 
3.1.9  DNA precipitation in ethanol / isopropanol 
Ethanol and isopropanol precipitation was used for the purification of DNA and RNA. 
Ionic concentration of the aqueous DNA and/or RNA solution was increased by 
addition of 1/10 volume 3 M sodium acetate solution (pH 5.2). About 2.5 times 
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volumes of ethanol/isopropanol were added. The DNA and/or RNA was incubated at 
-20°C for 30-60 min. Afterwards the sample was centrifuged at 13,000 rpm, the pellet 
was washed with 70% ethanol and dried for 10 min at 60°C. Then the DNA and/or 
RNA pellet was dissolved in the desired quantity of milli Q water or buffer.  
  
3.1.10 Concentration determination of nucleic acids  
To determine the concentration of DNA or RNA in a solution the optical density (OD) 
was measured. Nucleic acids have an absorption maximum at 260 nm and proteins 
absorb UV light maximally at a wavelength of 280 nm. Pure DNA exhibits an OD 
260/OD 280 ratio of up to 2. This ratio is inversely proportional to the amount of 
proteins present in the solution.  
  
For pure nucleic acids: 1 OD 260 corresponds to a concentration:  
dsDNA:                   
Oligonucleotide:   20 - 30 µg/ml 
ssDNA:                        33 µg/ml 
RNA:                            40 µg/ml 
 
A nanodrop spectrophotometer was used for quantification of DNA and RNA. 
 
3.1.11  Polymerase chain reaction (PCR) 
 
DNA sequence for the respective gene was obtained from the NCBI web site. 
Primers for PCR were designed based on the following general considerations: the 
length of the primer should be around 19 bp, the melting temperature (Tm) of the 
primer should be close to 60°C, and the nucleotide at the 3’ end should be either G 
or C. Primers used in the same PCR reaction were checked carefully to avoid 
formation of primer-primer dimers. 
The melting temperature of the primer was calculated according to the following 
formula: 
Tm = 4 (G+C) + 2 (A+T) 
  Methods 
 
                                                  35
3.1.12 PCR-setup 
Unless specified differently, PCR reactions were performed in a total volume of 50 µl. 
To avoid nonspecific annealing of the primers and undesired PCR amplification, all 
the constituents (Tab. 3.1) were pipetted on ice and transferred to a cycler (iCycler, 
BioRad) immediately. The PCR was performed along with corresponding positive 
and negative controls. For multiple PCR reactions, a master mix was made and 
respective templates were added in appropriate aliquots of master mix. 
Tab. 3.1: PCR reaction setup 
Detail End concentration 
DNA  template (cDNA, plasmid DNA)  2 ng/µl 
Primer sense 0.3 µM 
Primer antisense 0.3 µM 
Taq DNA polymerase 10x buffer 1x 
MgCl2 2 mM 
DNTPs 25 nM 
Taq DNA polymerase 1 U 
Made upto 50 µl with milli Q water  
 
The reaction parameters (temperature, cycle) were adapted to the respective PCR 
setup.  
 
The standard PCR program consists of the following steps: 
 
Initial denaturation                     94°C           5 min 
Denaturation                              94°C          45 s 
Annealing                            50–60°C          45 s                              30-35 Cycles 
DNA synthesis                          72°C            2 min 
Terminal DNA-Synthesis          72°C          10 min 
Cooled at 4°C.  
 
3.1.13 Generation of DIG probes 
Denatured PCR fragments can be used as probes in hybridizing experiments. For 
this purpose it is necessary to label a probe in order to make later detection possible. 
The incorporation of digoxigenin labeled nucleotides (DIG dNTPs, Roche 
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diagnostics) during the PCR amplification of DNA instead of dNTPs gives a non-
radioactive labelling alternative.  
The DIG PCR was setup as mentioned in Tab. 3.2. The labelling of the probe was 
always examined on the basis of slight gel retardation in agarose migration 
compared with similar nonlabelled PCR product. PCR products were cleaned by the 
Nucleotide Removal Kit (Qiagen). 
Tab. 3.2: Reaction setup for the synthesis of Probes 
Detail Volume 
Plasmid DNA 100 ng X µl 
Primer sense 20 µM 2 µl 
Primer antisense 20 µM 2 µl 
Taq DNA Polymerase 10x buffer 5 µl 
MgCl2 2mM 4 µl 
10x PCR DIG probe labelling mix (Roche) 5 µl 
Taq DNA polymerase 1 U 1 µl 
Made up to 50 µl with milli Q water 
3.1.14 Sequencing of DNA 
The sequencing of plasmids was performed by the Macrogen Incorporations in Seoul 
(South Korea).  
3.1.15 Purification of PCR-Products  
PCR products were cleaned up over spin columns (Qiagen) in accordance to the 
manufacturer data. 
3.1.16 Reverse Transcription 
cDNA synthesis 
About 5 µg of RNA were used for cDNA synthesis and volume was adjusted to 10 µl 
with DEPC water. One µl of oligo (dT) primer was added to RNA and mixture was 
incubated at 60°C for 5 min. In the meantime, master mix was prepared as follows: 
1 µl DEPC water, 1 µl 10 mM dNTPs, 4 µl 5x first strand buffer, 2 µl 0.1 M DTT and 1 
µl reverse transcriptase.    
Nine µl of master mix was added to each tube and tubes were incubated at 42°C for 
1 h followed by 15 min incubation at 70°C for cDNA synthesis.  
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PCR amplification 
A maximum of 1/10th volume of the reverse transcribed cDNA was used as template 
for the PCR reaction setup. 
 
3.1.17 Topo cloning 
Topo blunt (Invitrogen) or TA cloning (Invitrogen) was performed according to the 
instructions given by the manufacturer. 
 
3.1.18 Generation of Expression vector 
The pcDNATM 3.1 Directional TOPO® Vector (Invitrogen) was used as expression 
vector due to its rapid directional cloning of blunt end PCR products for expression in 
mammalian cells. This vector allows for high-level expression of proteins in most 
mammalian cells.  
 
 
 
 
 
 
Fig. 3.1 Directional blunt end cloning strategy: Directional blunt end cloning strategy using the 
pcDNATM 3.1 Directional TOPO® vector is shown. (Taken from Invitrogen catalog K4900-01). 
 
As shown in Fig. 3.1, a KOZAK sequence (CACC) which is complementary to a 
pcDNATM 3.1 Directional TOPO® vector end sequence, was added to the 5’ end of 
the CB2 coding signal.  
3.1.19 Isolation of genomic DNA from mouse tail biopsy 
3.1.19.1 For Southern blot application 
For the isolation of genomic DNA from mouse tail biopsy, approximately 0.5 cm long 
tail pieces were lysed overnight in lysis buffer containing proteinase K at 55°C and 
centrifuged at 13,000 rpm for 5 min. The supernatant was carefully removed and 
mixed with an equal volume of 100% isopropanol. The genomic DNA (white thread-
like precipitate) was then fished with a sterile pipette tip, transferred into 1 ml of 70% 
ethanol solution and centrifuged at 13,000 rpm. The pellet was washed with 70% 
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ethanol and dried at 50°C for 10 min. Afterwards the DNA pellet was dissolved in 100 
µl of milli Q water. 
 
3.1.19.2 For genotyping application 
For the quick isolation of genomic DNA from mouse tail biopsy (Truett, Heeger et al. 
2000), approximately 0.2 cm long tail pieces were incubated with alkaline lysis 
reagent at 95°C for 1h in PCR cycler. After cooling to 4°C, 75 µl of neutralization 
reagent was added, quickly vortexed, and then centrifuged at 5,000 rpm for 5 min. 1-
2 µl of supernatant was used for the genotyping PCR. 
 
3.1.20 Southern blot   
The restriction digestion and the agarose gel electrophoretic separation of DNA were 
performed as previously explained. About 20 µl (10-15 µg) of the genomic mouse 
DNA obtained from tail biopsy were digested overnight with 30 U of the restriction 
enzyme using the optimal temperature and buffer conditions indicated by the 
manufacturer. After electrophoresis the gel was gently shaken for 10 min in 0.25 N 
HCl to achieve DNA depurination. The agarose gel was then transferred to the 
alkaline denaturing solution and gently shaken for 30 min before transferring into 
neutralization solution for 30 min. After the neutralization step, using a Vacuum 
blotter (BioRad) DNA was transferred on a nylon membrane at a pressure of 5 bars 
for approximately 90 min in 10x SSC solution. DNA was then crosslinked to the 
membrane by UV irradiation (150 mJ, UVCROSS-left, Stratagene). The DIG probes 
used for screening were manufactured by PCR as described in 3.1.13. 
 
3.1.21 Isolation of RNA 
For the isolation and the analysis of RNA some precautionary measures were 
followed. For all buffers and solutions DEPC treated milli Q water was used. All used 
glassware was baked for at least 4 h at 180°C before use. Metallic parts such as 
spatulas, pincets or the homogenizer were washed thoroughly with RNase off and 
followed by sterile DEPC treated milli Q water. The RNA was isolated with TRIzol 
reagent (Invitrogen). A 100 mg tissue or 5x106 cells were treated in each case with 
1.6 ml TRIzol reagent. The tissue was homogenized in TRIzol reagent with a 
homogenizator (T8 ultra turrax, IKA) and passed through a 21 G needle at least 10 
times. Homogenized samples were left at room temperature for 5 min in 2 ml 
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eppendorf tubes to allow complete dissociation of nucleoprotein complexes. The 
homogenate was centrifuged at 5,000 rpm at 4°C for 5 min. The supernatant was 
then mixed with 1/10 volume 1-Bromo-3-chloro-propane by vortexing. The mixture 
was incubated for 3 min and centrifuged at 4°C at 11,400 rpm. The aqueous phase 
was carefully transferred into a fresh tube and mixed with an equal volume 
isopropanol and incubated for 10 min. Afterwards the sample was centrifuged at 4°C 
at 11,400 rpm. The resulting RNA pellet was washed with 75% ethanol. The pellet 
was dried in air for 10-15 min and dissolved in DEPC milli Q water by incubating 15 
min at 55°C. The RNA concentration was estimated by reading O.D. using the 
Nanodrop. 
 
3.1.22 RNA Electrophoresis 
To determine the quality of isolated RNA, denaturating formaldehyde gels were used. 
All apparatus were cleaned with milli Q water followed by RNAse off solution and 
DEPC milli Q water. 
For 1.2% agarose gel, 0.6 g RNase free agarose was dissolved in 45 ml DEPC milli 
Q water by boiling in a microwave. A 5 ml 10x FA buffer was added to the agarose 
solution. Then it was cooled down to 50-60°C with constant stirring. Before casting, 
900 μl of 37% formaldehyde and 1 μl ethidium bromide (5 mg/ml) were added. About 
5-10 μg of the isolated RNA diluted in 4 μl 5x RNA sample buffer were heated up for 
3 min to 65°C, then were cooled immediately on ice for 10 min. Samples were loaded 
on the gel and separated at 70 V in 1x FA gel buffer. The quality of the isolated RNA 
was judged under UV light on the basis of the ribosomal RNA bands or by the 
Bioanalyzer instrument (Agilent). 
3.1.23 Tissue preparation 
Isopentane was precooled on dry ice before the preparation. The tissue was 
removed and rinsed with PBS. Organ was quickly frozen with help of precooled 
isopentane in Tissuetek molds or for PFA fixation, it was transferred to a 50 ml 4% 
PFA containing solution. After overnight shaking at 4°C, it was transferred to 30% 
sucrose solution till the organs sink at the bottom of the tube at 4°C. Tissuetek 
cryomold plastic cassette bottom and corners were immersed in dry ice precooled 
with isopentane. Removed organs were kept in plastic mold until it solidified and 
were immediately stored at -80°C until further use.  
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3.1.23.1 Cryosectioning 
The prepared organs were sectioned in the cryostat (cm 3050 S, Leica) at a 
temperature of -18 to -24°C to a thickness of 12-20 µm. After cutting, the sections 
were dried for 10-15 min on a 42°C warm plate and fixed or stored at -80°C. 
 
3.1.23.2 Fixation of sections  
Dried sections were fixed with aqua poly/mount mounting medium (Polysciences) 
and allowed to dry at 4°C overnight in the dark prior to visualization with fluorescence 
under confocal microscope or fluorescent microscope. 
 
3.2 Protein biochemical and immunological methods 
 
3.2.1 Protein isolation from tissues 
100-600 mg tissue were homogenized with a homogenizer (T8 ultra turrax, IKA) in 1 
ml of lysis buffer in the presence of the complete mini protease inhibitor cocktails 
(Roche) for 3 X 20 s long pulses and then kept in an ultrasonicator bath (Sonoplus, 
Bandelin) for 30 s over 5 cycles. Following 15-30 min incubation on ice, the 
homogenate was centrifuged for 30 min at 13,000 rpm at 4°C. The supernatant was 
transferred to a new tube and one aliquot was used for protein measurement. 
 
3.2.2 Protein isolation from cells 
Cells were washed and scrapped off in ice cold PBS. Cells were pelleted by 
centrifugation at 1,000 rpm/ 5 min/ 4°C and lysed with STEN lysis buffer (200 µl for 6 
cm dish and 400 µl for 10 cm dish) or lysis buffer on ice for 30 min in the presence of 
protease inhibitor mix. The lysates were cleared by centrifugation at 12,000 rpm. 
Protein estimation was performed and 20 µg of protein were aliquoted from each 
sample. The samples were then boiled with loading dye. 
3.2.3 Estimation of protein concentration (BCA method) 
Samples were diluted appropriately and the BCA kit (Perbio) was used to analyze the 
protein concentrations in triplicates.   
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3.2.4 Immunoblotting 
After electrophoresis, proteins from a polyacrylamide gel were transferred to a 
nitrocellulose membrane using blotting chamber (BioRad). The transfer was 
confirmed by Ponceau S staining. The stain was removed by washing in PBS-T 
solution 10-15 min. Membrane was blocked with 5% Rotiblock reagent for 1 h. The 
blot was then incubated with appropriately diluted primary antibody solution for 2 h at 
room temperature or overnight at 4°C. The blots were washed 5 times each for 5 min 
with PBS-T and later incubated with appropriate secondary antibody conjugated to 
HRP (Horseradish peroxidase) for 1 h at RT. The blots were again washed with PBS-
T and chemiluminescent peroxidase substrate was used to visualize protein bands. 
Signals were measured and analyzed using an ECL imager (ChemiDocTM XRS, 
BioRad) or by using Hyperfilm (Amersham biosciences) and the Quantity One 
software package (BioRad). 
3.2.5 Immunoprecipitation 
Approximately 80-90% confluent 15 cm cell plate or tissue were lysed in 700 µl 
STEN-lysis buffer on ice for 10 min in presence of complete mini protease inhibitor 
cocktail (Roche). Lysates were cleared by centrifugation for 10 min at 14,000 rpm. An 
appropriate amount of primary antibody and 40 µl of protein-A sepharose beads were 
incubated overnight with cleared protein lysates at 4°C. The antigen-antibody 
complex bound to beads was separated by centrifugation for 5 min at 5,000 rpm and 
washed with STEN buffers. Beads were boiled with loading sample buffer, and 
loaded on polyacrylamide-SDS gel. 
 
3.2.6 Immunocytochemistry 
Cells were cultured on poly-L-lysine-coated glass coverslips to 50-80% confluence. 
Cells were fixed in 4% paraformaldehyde for 10 min followed by permeabilization with 
0.1% Triton X-100 for 10 min and blocking with 5% BSA for 1 h. Cells were incubated 
with desired primary antibody/antibodies, for example α-Giantin (golgi marker), 
Calnexin (endoplasmic reticulum marker) and LAMP I, II (lysosomal markers) at 
appropriate concentrations for 2 h in 1% BSA. Primary antibodies were detected by 
using Cy3 conjugated secondary antibodies (Dinova) diluted at 1:1000. Coverslips 
were mounted on glass slides using 15% Mowiol containing 50 mg/ml DABCO or 
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aqua poly/mount mounting medium. Images were acquired on a fluorescence-
inverted microscope (Zeiss). 
 
3.2.7 Hematoxylin and Eosin (H&E) staining 
Parafin embedded sections of wounds were deparaffinized by incubating slides in 
Xylol bath 2X5 min under the hood. This was followed by short 1 min incubations with 
decreasing ethanol gradient (100% to 50%). Slides were then icubated with milli Q 
water for 2-3 min followed by 45 sec incubation in 1% Hematoxylin solution. Slides 
were then washed 5X10 s with milli Q water. Followed by 10 s 70% ethanol wash. 
Further, slides were incubated 10 s in 0.1% Eosin solution. Slides were then 
incubated with increasing gradient of ethanol (80%-100%) prior to incubating 2X10 
min with Xylol solution. Excessive xylol was removed with clean tissue paper and 
slides were covered with Roti Histo-Kit II (Roth) mounting medium. Slides were 
allowed to dry prior to the microscopic visualization.  
3.3 Cell culture methods 
3.3.1 Common cell culture methods 
All cell lines were cultivated at 37°C in an incubator with 5% CO2 and humid 
atmosphere. Adherent growing cells were grown in tissue culture dishes on 6, 10 or 
15 cm diameter dishes. The growth medium was renewed twice a week. Antibiotic 
mixtures of penicillin and streptomycin (Pen/Strep) were used to minimize bacterial 
contamination. 
3.3.2 Passage of mammalian cells 
Almost confluent (80-90%) grown cells were passaged into a new culture dish. First 
the medium was removed and cells were washed with 10 ml PBS. Approximately 2 
ml of a trypsin/EDTA solution (Invitrogen) were added and the plate was incubated at 
37°C for 3-5 min to dislodge the cells. Trypsinization was inhibited by addition of 10 
ml growth medium. Cells were mixed well by pipetting up and down with a 10 ml 
glass pipette and transferred into a Falcon tube. The cells were pelleted by 
centrifugation (1,200 rpm, 2 min), resuspended in growth medium and seeded at 
suitable density.    
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3.3.3 Freezing and storage of cells 
A 15 cm confluent culture dish was passaged as above. Cells were resuspended in 5 
ml freezing medium with 10% DMSO and transferred with a sterile 1 ml pipette in 
cryotubes. The cells were stored overnight at –20°C prior to -80°C long term storage. 
 
3.3.4 Thawing of cells 
Cells were thawed in a 37°C waterbath as quickly as possible. In order to minimize 
the toxic effect of the DMSO, 5 ml fresh growth medium were added and cells were 
pelleted by centrifugation at 1,200 rpm for 2 min. The cell pellet was resuspended in 
the appropriate cell culture medium and seeded depending upon desired cell density 
in tissue culture dishes and cultivated under standard conditions. 
3.3.5 Culturing of HEK 293 and HeLa cells 
HEK and HeLa cells were grown in DMEM + 10% FCS + 1 mM sodium pyruvate + 
non-essential amino acids in an incubator at 37°C, 5% CO2 concentration and a 
humid atmosphere.  
3.3.6 Culture of CHO-K1-Cells 
CHO-K1 cells were grown in HAM´s F12 (Coon´s Modification) + 10% FCS  + 1 mM 
sodium pyruvate in an incubator at 37°C, 5% CO2 concentration and a humid 
atmosphere.  
3.3.7 Culture of L929 cells 
L929 cells were grown in RPMI 1640 medium + 5% FCS + 1 mM sodium pyruvate in 
an incubator at 37°C, 5% CO2 concentration and humid atmosphere. 
3.3.8 Cell counting 
The cell number was determined using a Neubauer modified cell chamber. The cell 
number per ml was calculated by determining the average number of cells in the 4 
large squares and multiplying by 104.    
3.3.9 Mycoplasma test  
Mycoplasma detection test was performed once a month on the mostly used and 
newly coming cell lines. Minera Biolabs, Venor Ge® M Kit was used for this purpose. 
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3.3.10 Transient and stable transfection of fluorescent tagged eukaryotic cells  
Cells were grown to 60-80% confluence before transient transfection. Transfection 
was performed using Lipofectamine reagent (Invitogen) according to the 
manufacturer's instructions. To generate stable cell lines expressing a fluorescent 
tagged CB2 plasmid, two days after transfection, cells were seeded/diluted and 
maintained in selection medium, containing 400 µg/ml G418. Medium was replaced 
every third day with fresh selection medium. Clonal expression was examined initially 
by fluorescent microscopy and clones for further study were selected and expanded. 
 
3.3.11 eCFP and eGFP visualization 
GFP excitation variant eGFP, enhanced green fluorescent protein (GFPmut1; 
(Cormack, Valdivia et al. 1996)) and  GFP emission variants  ECFP (enhanced cyan 
fluorescent protein) contains six amino acid substitutions, one of which shifts the 
emission spectrum from green to cyan (Heim and Tsien 1996; Miyawaki, Llopis et al. 
1997) were used in this work. 
 
Tab 3.3: Excitation and emission maxima of eCFP and eGFP fluorescent proteins. 
 
Protein Excitation maxima (nm) 
Emission 
maxima (nm) 
Em  
(cm–1 M–1) Quantum yield 
EGFP 488 507 55,000 ~60 
ECFP 433 (453) 475 (501) 26,000 ~40 
   
Appropriate filter set no. 424920 (Zeiss) were used to screen fluorescence proteins. 
For cyan filter with band pass of 390-440 nm and for green filter with 450-490 nm 
was used. 
3.3.12 Confocal laser scanning microscopy 
Cells were observed using a laser scanning confocal microscope (Olympus) 40X1.40 
NA water immersion objective, pinhole of 35, and electronic zoom of 1 or 3. The GFP 
or CFP was excited using 458 nm Argon/Crypton laser and detected with a 515-540 
nm band pass filter. The Texas red-conjugated transferrin (TR) was exited at 543 nm 
and detected with a long pass band filter 570 nm. 
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3.3.13 Co-localization of CB2 with transferrin 
Cells stably expressing fluorescent tagged CB2 receptor were grown on coverslips 
treated with poly-L-lysine to ~50% confluency and serum-starved for 60 min prior to 
30 min incubation with Alexa red conjugated TR. Cells were washed with PBS and 
fixed for 20 min with 4% PFA in PBS. The cells were washed twice with PBS and 
fixed with Mowiol prior to confocal visualization. 
3.3.14 Erk phosphorylation 
Erk-MAPK Assay. Cells grown to 80% confluence in 24-well plates were placed in 
medium containing 0.5% FCS for 24 h before assay. After treatment, cells were 
washed twice in buffer A (50 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM Na4P2O7, 50 
mM NaF, 1 mM EDTA, 20 mM ß-glycerophosphate, 1 mM EGTA, 2 mM Na3VO4) and 
lysed for 15 min in 100 µl of buffer A containing 1% (v/v) Triton X-100, 100 U/ml 
aprotinin, 20 mM leupeptin, 0.2 mg/ml phenylmethylsulfonyl fluoride and 2 mM 
dithiothreitol (Bouaboula, Bourrie et al. 1995). Solubilized cell extracts were 
centrifuged at 14,000 rpm for 15 min. The protein content in the supernatant was 
determined using a micro BCA protein assay kit (Pierce Chemical Co., Rockford, IL) 
and 20 µg of proteins were analyzed for Erk-MAPK activity using Western blot 
technique. The extent of phosporylated p42/p44 Erk-MAPK proteins were detected 
by using phosphorylated p42/p44 Erk-MAPK specific antibody and total Erk-MAPK 
protein were detected using total p42/p44 Erk-MAPK specific antibody (Cell 
Signaling). 
3.3.15 Effect of agonist and antagonist on internalization 
Agonists or antagonists were dissolved in HymaxDMSO (Sigma). Only DMSO was 
used as vehicle control. Cells were grown on a poly-L-lysine coated coverslips. Prior 
to the experiment, cells were serum starved overnight and then were incubated for 
different time intervals with corresponding agonist and/or antagonist. The cells were 
fixed with 4% PFA prior to fluorescent visualization. 
3.3.16 Bone marrow culture 
3.3.16.1 Bone marrow cell isolation 
After removing all muscle tissues with gauze from the femurs and tibias of mouse, 
the bones were placed in a 10 cm dish with ice cold PBS, washed twice with PBS 
and transferred into a fresh dish. Both ends of the bones were cut with scissors and 
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the marrow was flushed out using 2 ml of PBS with a syringe and a 25 G needle. The 
tissue was suspended and passed through a 30 µm nylon mesh (Miltenyi Biotec) to 
remove small pieces of bone and debris. Cells were centrifuged at 1,200 rpm for 5 
min, resuspened in RPMI medium and then counted.  
 
3.3.16.2 Bone marrow cell differentiation (macrophages and dendritic cells) 
Bone marrow cells (3-5 x 106) were suspended in 10 ml RPMI medium containing 
70% fresh RPMI medium with 5% FCS, Pen/Step, ß-mercaptoethanol (50 µM end 
concentration), L-glutamine and 30% of the L929 supernatant (containing rGM-CSF) 
on a non-treated Petri dish. Cells were split on day 3 by dislodging in PBS containing 
2 mM EDTA. To remove nonadherent granulocytes without dislodging clusters of 
developing dendritic cells that were loosely attached to firmly adherent macrophages, 
the cultures were fed every second day by gently swirling the plates, aspirating 75% 
of the medium, and adding back fresh medium with GM-CSF. At day 7, adherent 
cells (mostly macrophages) or suspension cells (mostly dendritic cells) were used for 
FACS analysis or for RNA isolation. 
 
3.3.17 Isolation of peritoneal macrophages 
Macrophages were collected by peritoneal lavage from Cnr2-eCFP mice and wild 
type sibling mice by intraperitoneal injection of 2 ml 30% sucrose in PBS. The cells 
were separated by centrifugation and washed and resuspended in RPMI 1640 
medium containing 5% FCS. Cells were counted and used for FACS analysis.    
 
3.3.18 Isolation of splenocytes, lymph node and thymus cells 
For FACS analysis, mRNA and immunoprecipitation (IP) analysis, mice were 
sacrificed by cervical dislocation. Organs were removed, washed quickly with sterile 
PBS/HBSS buffer to remove the blood and adhering material. For mRNA analysis, 
organs were and quickly crushed with help of liquid nitrogen in presence of Trizol and 
processed further. For FACS analysis, organs were gently pressed with a Nylon 
mesh (Milteyi) of pore size 30 µm. Cells were centrifuged and the pellet was 
resuspended with fresh buffer prior to FACS analysis. For IP, organs were lysed as 
explained in 3.2.5.    
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3.3.19 FACS analysis 
Flow cytometry data files were collected on an LSR-II flow cytometer (Becton 
Dickinson), equipped with standard violet, blue, and red lasers and standard filter 
sets. Flow cytometry data were analyzed with the FlowJo© software (TreeStar, 
Ashland, Oregon). 
3.4 ES cells 
3.4.1 Preparation of feeder cells  
Female CD1 mice were paired with transgenic male mice, containing a Neomycin 
resistance gene. Next day, female mice were observed for the appearance of a plug 
(vaginal deposits), which is an indicator for pairing. Plug-positive female mice were 
sacrificed 12-14 days by cervical dislocation. An uterus containing mouse embryos 
was washed twice with HBSS. Embryos were seperated of from the placentas by 
opening uterus. Attached remaining organs were removed. The embryos were cut 
into small pieces and incubated in 30 ml Trypsin/EDTA for 15-20 min (37°C, 5% 
CO2), shaked every three min. Centrifuged for 2 min at 1,200 rpm. The remaining 
pellet was resuspended in 25 ml fibroblast medium and plated in 15 cm cell culture 
plates. The cells were subcultured 2-3 days and stored further for use. 
3.4.2 ES cell culture 
ES cells of MPI2 and R1 origin were grown on ES cell culture medium on growth 
arrested embryonic feeder cells in an incubator at 37°C, 5% CO2-concentration and 
humid atmosphere. Culture medium was changed every 24 h and cells were 
trypsinated every second day. 
3.4.3 ES cell electroporation 
Approximately 3X15 cm plates of ES cells were used for two electroporations of the 
constructs. Prior to trypsinization, about 1-2 h medium was changed. To trypsinize 
ES cells, culture medium was removed and 8-10 ml trypsin per plate was added. 
Plate was incubated 3-5 min to obtain single cell suspensions. Trypsin was 
inactivated by addition of 5 ml ES cell medium. The cell suspension was transferred 
into a 50 ml tube. Cells were counted with a hematocytometer. Aliquots were made 
to obtain 2 x 107 cells per 15 ml tube. Cells were pelleted by low-speed 2,000 rpm 
centrifugation. The cells were resuspened in 10 ml PBS. The cells were pelleted and 
resuspended in 700 µl of PBS such that the final volume was 800 µl.  
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The electroporation cuvette was prepared by addition of linearised plasmid 20-25 µl 
(1 mg/ml) and the ES cells. For electroporation, the suspension was mixed well and 
electroporated at 250 V and 500 µF. ES Cells were left at RT for 10 min and then 
transferred into 10 ml ES medium. ES cells were platted into 4 x 15 ml dishes, pre-
plated with G418 resistant embryonic fibroblast cells and cultured in selection 
medium containing G418 (170 ng/ml) for 7-9 days with fresh medium change 
everyday. The ES cell colonies were harvested. 
3.4.4 Isolation and identification of recombinant ES cell clones 
The growth medium was removed from ES cell plates and 25 ml PBS were added. 
The colonies were picked with a glass micropipette and transferred to the 24 well 
plates containing a drop of trypsin. A fresh 500 µl ES medium was added to each 
well and mixed with a pipette to obtain single cell suspensions. Embryonic fibroblast 
cells were added and ES cells were further cultured for 48 h with medium change 
after 24 h. The cells were trypsinized by adding 2-3 drops of trypsin and incubating 
plate at 37°C for 5-8 min. The cells were resuspended in 1 ml per well in freezing 
medium and 750 µl aliquots were frozen. The remaining cell suspension was kept in 
culture in the 24 well plates. After 4-7 days, the colonies were lysed in 300 µl lysis 
buffer for DNA isolation and incubated for 2 h at 52oC. To precipitate DNA 150 µl 
saturated NaCl and 900 µl absolute ethanol was added and mixed well. The DNA 
precipitate was transferred with a disposable micropipette tip into a 1.5 ml tube filled 
with 70% ethanol. The tube was centrifuged for 5 min at 12,000 rpm. The 
supernatant was removed and the pellet was air dried for 20-30 min. Pellet was 
resuspended in 100 µl milli Q water. Recombinant clones were identified by Southern 
blot or PCR analysis. 
 
3.4.5 Preparation of recombinant ES cell clones 
Positive clones were thawed and plated on 6 cm dishes pre-plated with embryonic 
fibroblast cells. The ES cell medium was changed every 24 h. When colonies were 
grown large enough (usually after 3-5 days) cells were split into 6 x 6 cm dishes 
preplated with embryonic fibroblast cells. 5 dishes were frozen as described above 
for further use. The remaining cells were again subcultured into 6 x 6 cm dishes and 
immediately used for chimera generation. 
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3.5 Generation of knock-in chimeric mice 
3.5.1 Generation of injection chimera 
Blastocyts were harvested from super ovulated C57BL/6J or CD1 female mice by 
flushing the uteri with M2 medium. Blastocytes were washed in M16 medium and 
stored in a CO2 incubator. 
ES cell medium was removed and 2 ml trypsin was added per plate. The plates were 
incubated 3–5 min to obtain single cell suspensions. Trypsin was inactivated by 
addition of 5 ml ES medium. The cells were pelleted by low speed centrifugation at 
2,000 rpm for 2 min. The pelleted cells were resuspended in 3 ml ES medium and 
replated into the same 6 cm dish. About 15 blastocysts and approximately 400 ES 
cells were added into the injection chamber with M2 medium and the blastocysts 
were microinjected. The injected blastocysts were transferred into a fresh drop of 
M16 medium and stored in a CO2 incubator until all blastocysts were injected. 
Blastocyts were transferred into pseudo pregnant foster mice. This was done by the 
microinjection service of the House for Experimental Therapy (HET, Bonn). 
The 8 - 24 weeks old pseudo pregnant fosters were paired with vasectomized males 
overnight. After 20-25 days chimeras were obtained. Germ line transmission was 
evaluated by coat colour and the genotypes of the transgenic mice were further 
determined using Southern blot as well as PCR. 
3.5.2 Deletion of the neomycin gene 
Germ line chimeras were further bred with wild type mice to obtain the F1 generation. 
Mice carrying the Cnr2-CFP-neo gene were bred to PGK-Cre transgenic mice 
(Lallemand, Luria et al. 1998) to delete the neomycin gene. The elimination of the 
neomycin gene was confirmed by an allele specific PCR analysis as well as by 
Southern blot analysis.  
3.5.3 Breeding and animal facility  
For the described experiments Cnr2-eCFP and Cnr2-eGFP animals were bred in the 
HET facility. The animals were held in artificial day-night cycle: Lighting from 7:00 to 
19:00 clock, darkness from 19:00 to 7:00 clock. The animals were housed in groups 
and received water and food ad libitum. 
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3.6 Wound healing experiments 
Mice were anaesthetized by intraperitoneal (i.p.) injection of ketamine (75 mg/kg) / 
xylazine (5 mg/kg). Two full-thickness 4 mm diameter excisional wounds were made 
on both sides of the dorsal midline by excising skin and panniculus carnous as 
described (Werner, Smola et al. 1994). Wounds were left uncovered and harvested 
at different time points after injury. Mice were kept separately in cages to prevent 
fighting and no self-induced trauma was observed in control or mutant mice. 
Littermates of the same sex were used for the analysis of wound closure. Wound 
closure was determined as the percentage of distance covered by the epidermis 
between the wound edges. For histological analysis, dissected wounds were fixed 
overnight in 4% formaldehyde or in 95% ethanol/1% acetic acid, followed by 
dehydratation through a graded ethanol series and embedding in paraffin. Sections 
from the middle of the wound were stained with HE (3.2.7). Histological sections 
were used to determine the epithelial length and area of wound by using the measure 
and area function of the Image J or Openlab 4 program. The percentage of the 
wound closure for open wound is calculated by 100 X (the the sum of the left and 
right epithelial wound length / the total wound length).   
3.7 Contact hypersensitivity  
DNFB (1-fluoro-2,4 dinitrobenzene, Merck) was diluted in acetone/olive oil (4:1) 
immediately before use. Mice were sensitized by painting 50 µl of 0.2% DNFB on the 
shaved abdomen on two consecutive days. Controls were treated with 50 µl acetone: 
olive oil. For elicitation of CHS, ears of mice were painted with 10 µl of 0.3% DNFB 
on day 5. Ear thickness was measured 48 h after the challenge using an engineer's 
micrometer (Oditest, Fa. Kroeplin, Schluechtern, Germany) and ear swelling was 
calculated in each mouse as the difference in ear thickness between the 
unchallenged (left) and the challenged (right) ear. 
3.8 Neuropathy pain model 
Under 2% isoflurane anaesthesia and aseptic conditions the right sciatic nerve was 
exposed at mid-thigh level. Approximately one-third to one-half the diameter of the 
nerve was tightly ligated with 9-0 silk sutures. The wound was closed. After 4 days 
the mice were sacrificed, spinal cord was removed and fixed in 4% PFA overnight 
followed by transfer into the 30% sucrose solution till it sank. The tissue was fixed 
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with tissuetek and cryosections were made. The sections were then visualized under 
fluorescent microscope after fixation with aqua poly/mount mounting medium.    
 
3.9 Statistical Methods 
The descriptive statistics were performed on the basis from average values and their 
standard errors (S.E.M.). All raw data were listed with the spreadsheet program 
EXCEL® (Microsoft) and evaluated with the statistics program Prism 4 (graph PAD 
software). Depending upon the conditions parametric or non-parametric test was 
used. Average value comparisons in pairs were examined with Students t-test or the 
man Whitney U-test for statistical significance. Differences were termed as significant 
if the probability (p), p < 0.05 and were called as very significant with p < 0.01. 
 
3.10 Used databases and programs 
The human and murine genome sequences can be searched on the Golden Path 
browser of the University of Santa Cruz (the USA) under http://genome.ucsc.edu, the 
Ensembl Browser under http://www.ensembl.org, and with the NCBI under 
http://www.ncbi.nlm.nih.gov/genome/guide/. 
NCBI Homepage (http://www.ncbi.nlm.nih.gov/) 
On the homepage "National Centres for of the Biology and Information" (NCBI) are 
numerous links to programs and databases. Frequently used are mentioned below: 
NCBI mouse genome resources: 
http://www.ncbi.nlm.nih.gov/genome/guide/M_musculus.html 
Under mouse genome resources, data from Mouse genome sequencing project was 
accessed. 
BLAST (Basic Local Alignment Search Tool, [Altschul et al., 1990]): 
http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/ 
The Blast algorithm was primarily used for similarity searches in sequence 
databases. 
 
DNAStar and Vector NTI 7: 
With help of DNAstar 6 (Dnastar Inc.) and Vector NTI 7 (Invitrogen) programs 
restriction maps from DNA sequences and vector maps for cloning of plasmids were 
made.
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4 Results 
Our group have been using metallic ear tags for the management of mouse colonies 
for more than 10 years and tagged well over 50,000 animals from numerous mice 
strains, including many different knock-outs. These tags are generally well tolerated. 
However, severe ulcerations were observed in the head and neck regions of 
cannabinoid receptor double knock-out mice as a result of frequent scratching 
around ear tags (Karsak, Gaffal et al. 2007). These necrotic lesions initially 
developed around the ear tag as shown in Fig. 4.1. 
 
 
Fig. 4.1 Macroscopic views of ear-tagged double knock-out mice: Ears of animals with 
(B) or without (A) allergic response towards clips with high nickel content leading to chronic 
ulceration (B). 
 
4.1 Wound healing of cannabinoid double knock-out animals 
Since localized necrotic lesions initially developed around the ear tag, impairment of 
wound healing process can possibly potentiate the formation of observed skin 
lesions. In order to investigate this possibility, full-thickness excision wounds were 
inflicted on animals by removing skin and panniculus carnosus on either side of the 
dorsal midline. Wounds were left uncovered and excised 3, 5 or 13 days after injury 
(Werner, Smola et al. 1994; Werner and Grose 2003; Bamberger, Scharer et al. 
2005). 
For histological analysis bisected wounds were fixed and sections were analyzed 
visually (day 3 and day 13) for wound healing impairments. Sections (6 μm) from the 
middle of the 5-day wounds of (A) Cnr1+/+/Cnr2+/+ and (B) Cnr1-/-/Cnr2-/- mice were 
stained with haematoxylin/eosin and used for morphometric analysis. Only littermates 
of the same sex were used for direct histological comparison. Morphometric analysis 
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resulted in no genotypic differences. For example ethanol fixed morphological 
analysis for 5 day wound experiment is shown here percentage of closure (Cnr1-/-
/Cnr2-/-, 72.07 ± 21.23% vs. Cnr1+/+/Cnr2+/+, 63.18 ± 24.65; p<0.26) (Fig. 4.2 C), 
epithelial length (Cnr1-/-/Cnr2-/-, 2.41 ± 1.21 mm vs. Cnr1+/+/Cnr2+/+, 2.60 ± 0.55 mm; 
p<0.92) (Fig. 4.2 D)  and  total area (Cnr1-/-/Cnr2-/-, 0.18 ± 0.06 mm2  vs. 
Cnr1+/+/Cnr2+/+,  0.24 ± 0.09 mm2; p<0.06) (Fig. 4.3 E).  
 
Fig. 4.2 Wound healing experiment: Ten to 12-week-old mice were anaesthetized with 
ketamine/xylazine. Four full-thickness excisional wounds (5 mm diameter) were generated on the 
shaved back, two on each side of the vertebral column, by excising skin and panniculus carnosus. For 
histological analysis bisected wounds were fixed overnight in 4% PFA in PBS or in 95% ethanol/1% 
acetic acid, followed by paraffin embedding. Sections (6 μm) from the middle of the 5-day wounds of 
(A) Cnr1+/+/Cnr2+/+ and (B) Cnr1-/-/Cnr2-/- mice were stained with haematoxylin/eosin and used for 
morphometric analysis. Only littermates of the same sex were used for direct histological comparison. 
Morphometric analysis resulted in no genotypic differences in (C) percentage of closure (D) epithelial 
length(epi length) and (E) total area. 
D: dermis, E: epidermis, G: granulation tissue, H: hyperproliferative wound epidermis, ES: eschar, M: 
muscle (Panniculus carnosus) 
 
Cannabinoid double knock-out mice were of mixed genetic background of C57BL/6J 
and 129/Sv strains whereas CB1 and CB2 knock-out animals were of C57BL/6J 
background.  Thus control animals of C57BL/6J background were also included in 
the experiments (Tab. 4.1). 
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Expt No. Study group Control group Sex Remark 
1 Cnr1-/-/Cnr2-/- Cnr1+/+/Cnr2+/+ M 
Slight tendency was 
seen. 5 day wound 
2 
Cnr1-/-, Cnr2-/-,   
Cnr1-/-/Cnr2-/- 
C57BL/6J, 
Cnr1+/+/Cnr2+/+ 
F 
No strong tendency  
5 day wound 
3 Cnr1-/-/Cnr2-/- Cnr1+/+/Cnr2+/+ M 
No tendency was 
observed. 5 day wound 
4 Cnr1-/-/Cnr2-/- Cnr1+/+/Cnr2+/+ M 
No tendency was 
observed. 13 day wound 
 
Tab 4.1 Summary of wound healing experiments: Indicating that wound healing 
impairment is not the cause for the lesions seen in the Cnr1-/-/Cnr2-/- knock-out animals. N=4 
animals per group. 
 
Both PFA and ethanol fixed wound slides were initially analyzed for the wound 
healing parameters like percentage of wound closure, epithelial length and total area. 
In the initial 5 day wound experiment, PFA fixed wound samples showed no 
significant difference in the percentage wound closure of Cnr1−/−/Cnr2−/− mice 
compared to wild type mice (Cnr1-/-/Cnr2-/-, 95.0 ± 10 vs. Cnr1+/+/Cnr2+/+,86.7 ± 11.94 
%; p<0.31) but in parameters like epithelial length (Cnr1-/-/Cnr2-/-, 1.73 ± 0.32 mm  vs. 
Cnr1+/+/Cnr2+/+,  2.75 ± 0.59 mm; p<0.03) and total area (Cnr1-/-/Cnr2-/-, 0.18 ± 0.05 
mm2 vs. Cnr1+/+/Cnr2+/+, 0.38 ± 0.13 mm2; p<0.01) significant difference was 
observed. However, from the same wound samples when fixed with ethanol showed 
no difference in any of the wound healing parameters, percentage of closure (Cnr1-/-
/Cnr2-/-, 96 ± 7.3% vs. Cnr1+/+/Cnr2+/+, 79.14 ± 17.87; p<0.14), epithelial length (Cnr1-/-
/Cnr2-/-, 1.9 ± 0.52 mm vs. Cnr1+/+/Cnr2+/+, 1.96 ± 0.52 mm; p<0.95) and total area 
(Cnr1-/-/Cnr2-/-, 0.19 ± 0.03 mm2  vs. Cnr1+/+/Cnr2+/+,  0.23 ± 0.08 mm2; p<0.53). Thus, 
I termed this result as tendency (Tab. 4.1, Expt. 1).  
Upon further experiments with 5 day wound and 13 day wound, I found no significant 
difference in the wound healing parameters  of Cnr1−/−/Cnr2−/− mice compared to wild 
type mice. The results for 5 day wounds are summerized in Tab. 4.1. The results for 
13 days wounds showed no significant difference ( % of closure (Cnr1-/-/Cnr2-/-, 96.0 
± 7.2 vs. Cnr1+/+/Cnr2+/+,79.15 ± 17.86 %; p<0.14), epithelial length (Cnr1-/-/Cnr2-/-, 1.9 
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± 0.52 mm  vs. Cnr1+/+/Cnr2+/+,  1.96 ± 0.52 mm; p<0.14) and total area (Cnr1-/-/Cnr2-/-, 
0.23 ± 0.1 mm2 vs. Cnr1+/+/Cnr2+/+, 0.19 ± 0.03 mm2; p<0.95)).  
 
Thus, it can be concluded that wound healing impairment did not cause the lesions 
seen in the knock-out animals. 
 
The aforementioned wound healing experiments were carried out in collaboration 
with Prof. Sabine Werner (Zurich). The following work of contact hypersensitivity 
model was done with collaboration with Dr. Meliha Karsak, Jennifer Rehnelt and Dr. 
Evelyn Gaffal (Bonn). 
 
 
4.2 Contact hypersensitivity model in cannabinoid receptor knock-out animals 
As we observed no skin ulcerations in single Cnr1−/− or Cnr2−/− knock-outs or in any 
other mouse strain but in Cnr1−/−/Cnr2−/− double knock-out mice, the skin ulcerations 
appeared to be prominent with ear tags containing high nickel content (65 to 70%). In 
these cases, skin ulcerations were observed in 88 out of 304 (29%) animals, possibly 
due to an increased allergic response in the Cnr1−/−/Cnr2−/− mice. To verify this 
hypothesis the cutaneous contact hypersensitivity model (Knop, Stremmer et al. 
1982; Schwarz, Beissert et al. 2000) was evaluated in these mice.  
In this well-established experimental model, mice without any skin lesions and ear 
tags were exposed to repeated obligate contact with the DNFB allergen to trigger a 
specific cutaneous T-cell mediated allergic response.  To sensitize the mice, DNFB 
was repeatedly administered to the abdominal skin and subsequently challenged by 
DNFB application to the ear. Allergic ear swelling was measured over a time course 
of 24 days. As shown in Fig. 4.3, a strikingly increased allergic response in knock-out 
Cnr1-/-/Cnr2-/- mice was observed as compared to wild type Cnr1+/+/Cnr2+/+ mice. The 
genotype difference was particularly greater 48 h after the second (Cnr1-/-/Cnr2-/-, 
1.89 ± 0.16 mm vs. Cnr1+/+/Cnr2+/+, 0.71 ± 0.05 mm; p<0.01) and third DNFB 
challenge (Cnr1-/-/Cnr2-/-, 3.83 ± 0.29 mm vs. Cnr1+/+/Cnr2+/+, 1.64 ± 0.09 mm; 
p<0.01). 
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Fig. 4.3 Contact allergy in cannabinoid receptor deficient mice: (A) Cnr1−/−/Cnr2−/− and 
Cnr1+/+/Cnr2+/+ mice were sensitized (indicated by “s”) with DNFB on the shaved abdomen. On day 5, 
mice were challenged (indicated by “c”) with DNFB on the right ear. A second and third challenge was 
performed on day 13 and 21. Shown is the mean ear swelling over time ± SEM of a representative 
experiment with nine mice per group. Statistical significance was evaluated with the Wilcoxon-Mann-
Whitney two-sample test (**P<0.01). This experiment was independently repeated four times with 
similar results. (B) Cnr1−/−/Cnr2+/+, Cnr1+/+/Cnr2−/−, and Cnr1+/+/Cnr2+/+ mice were sensitized as 
described in (A). Ear swelling 48 h after the third challenge of a representative experiment with eight 
mice per group is shown. Similar results were obtained in four independent experiments with a total of 
23 mice (**P < 0.01). (C) Contact allergic response in C57BL/6J mice after treatment with the 
indicated CB receptor antagonists. Ear swelling 48 h after the second challenge of a representative 
experiment with 10 mice per group is shown. Similar results were obtained in four independent 
experiments with a total of 25 mice (***P < 0.001). Errors bars in (B) and (C) indicate SEM. (Karsak, 
Gaffal et al. 2007) 
 
 
To further examine the allergic response of DNFB in animals with a single deletion in 
CB1 or CB2 receptors, we performed a similar experiment on these animals. As 
shown in Fig. 4.3 B, Cnr1-/- and Cnr2-/- mice show a similarly pronounced increase of 
allergic ear swelling.  
To obtain independent evidence for the role of CB1 and CB2 receptors in the 
regulation of CHS, the CB1 receptor antagonist SR141716A (Rimonabant) and the 
CB2 receptor antagonist SR144528 were administered in wild type mice. After the 
induction of CHS, animals received three injections of the corresponding antagonist, 
30 min before and after each challenge. In these cases, ear swelling was significantly 
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increased in treated mice as compared with control mice (Fig. 4.3 C), further 
supporting the role of both receptors in CHS. 
Due to the possibility that administration of cannabinoids such as ∆9-THC might 
attenuate CHS in wild type animals, after CHS was induced, mice were injected with 
∆9-THC (5 mg per kilogram of body weight, administered subcutaneously) 30 min 
before, as well as 24 and 48 h after DNFB challenge. Ear swelling was measured in 
these animals over a course of 21 days (Fig. 4.4). 
 
 
Fig. 4.4 Effect of cannabinoid receptor agonist on contact allergic response: Contact allergic 
responses in C57BL/6J mice after subcutaneous (A) or topical (B) treatment with the agonist's ∆9-THC 
and HU-308 or with vehicle alone. Error bars indicate SEM. (Karsak, Gaffal et al. 2007) 
 
∆9-THC significantly decreased ear swelling (Fig. 4.4 A). A similar therapeutic effect 
of ∆9-THC was observed after topical application of 30 µg of ∆9-THC 30 min before, 
as well as 24 and 48 h after DNFB administration (Fig. 4.4 B). The CB2-specific 
agonist HU-308 either showed no efficacy or even an increased allergic response 
was observed in contrast after subcutaneous or topical application (Fig. 4.4, A and 
B). 
As the CB2 receptor seems to play an important role in the cutaneous 
hypersensitivity, the cutaneous expression of CB2 receptors at protein levels should 
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be further investigated. Unfortunately, we and other labs often observe non specific 
CB2 staining in tissues of knock-out animals with commercially available CB2 
receptors antibodies, despite many efforts by competent labs. Therefore one of the 
aims of the following work was to generate fluorescent tagged CB2 receptors using a 
knock-in approach. CB2 receptor is denoted as Cnr2 receptor, but henceforth in my 
work I use more common denotation CB2, instead of Cnr2. 
 
4.3 Expression vectors for the CB2 receptor   
In order to determine if tagging of a fluorescent protein to the CB2 receptor interferes 
with its subcellular localization and its function, two versions of fusion proteins, one 
using GFP and the other using CFP were generated. A vector system commonly 
used for expression of GPCRs in tissue culture cells was used.  
 
4.3.1 Generation of fluorescent tagged CB2 receptors 
The CB2 receptor was modified at the C-terminus by in frame addition of the eCFP or 
eGFP sequence to generate CB2-eCFP-N1 and CB2-eGFP-N1 vectors. Initially the 
CB2 receptor sequence containing an additional 1.5 kb fragment homologous to 5 ´ 
UTR upstream of the CB2 coding sequence was amplified by PCR from 129/Sv ES 
cell genomic DNA. By using appropriate primers, a Pac I restriction site (TTAATTAA) 
was added to the 5´ end of the genomic CB2 sequence (NM_009924) and the CB2 
stop codon sequence (TAG) was replaced by the glycine coding sequence (GGA) 
yielding a fragment of 2.5 kb.  
Additionally, Age I restriction site (ACCGGT) was cloned in at the 3´end. This 
modified CB2 fragment was cloned in a pCR®blunt II TOPO vector (Invitrogen), 
referred as 2.5 kb-CB2 PCR blunt-TOPO. This vector was digested with the 
restriction enzymes Xho I and Age I. The fluorescent protein containing vectors 
pEGFP-N1 or pEGFP-N1, were also digested with the same enzymes. The resulting 
fragments were separated by gel electrophoresis and recovered from the gel using 
an agarose gel extraction kit (Qiagen). An insert containing the CB2 coding region 
was then ligated to the eGFP or eGFP containing vector (Fig. 4.5). 
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Fig. 4.5 Restriction digestion of pECFP-N1 vector and 2.5 kb-CB2 PCR blunt TOPO vectors: 
eCFP and CB2 short arm containing vectors were digested with XhoI and Age I restriction enzymes 
and fragments were analyzed by agarose electrophoresis (lanes 1 and 3 respectively), lanes 2- 4 
show undigested vectors. M: 1 kb Invitrogen molecular ladder. 
 
This resulted in the C-terminal CB2 fusion with the linker sequence of the six amino 
acids GPVAT (Fig. 4.6). This vector was used as template for the generation of 
expression vectors for cell culture experiments and the generation of knock-in mice.  
 
      .…....  T     E     A     D     V     K    T    T     G     P     V      A      T     M    V     S      K     G…….. 
…….. CAGAGGCTGATGTGAAAACCACC GGACCGGTCGCCACC ATGGTGAGCAAGGGC……... 
               C-terminal CB2 sequence                  Linker sequence          N-terminal GFP/CFP sequence 
 
Fig. 4.6 Sequence of the C-terminal GFP/CFP fusion: Primers were selected such that the stop 
codon sequence was modified to the amino acid sequence of glycine. Black: C-terminal sequence of 
the murine CB2 receptor, red: linker sequence, green: GFP/CFP N-terminal sequence. 
 
For the CB2-eCFP or CB2-eGFP sequence amplification D_mCB2_KZ_F and GFP 
Stop Not1 R primers were used for the generation of expression vectors. This 
resulted into amplification of a 1776 bp PCR fragment (lane 3 and 4, Fig. 4.7). For 
the amplification of the control CB2 vector D_mCB2_KZ_F primer and mCB2-exon 
stop rück primer were used. This resulted into amplification of a 1041 bp fragment 
(lane 2, Fig. 4.7). 
The PCR products were verified by agarose gel electrophoresis and by sequencing.  
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Fig. 4.7 Gel electrophoresis of PCR products CB2-eCFP, CB2-eGFP and CB2: In each lane 3 µl of 
the PCR product of the appropriate vector was loaded and separated on a 1% agarose gel at 120 V. 
Lane M show 1 kb ladder (Invitrogen), lane 1 show CB2 and lane 2,3 shows CB2-eCFP and CB2-
eGFP PCR fragments. 
 
In Fig. 4.7, the expected amplified products of 1.8 kb for CB2-eCFP (lane 2) as well 
as CB2-eGFP (lane 3) and 1 kb for CB2 (lane 1) are shown. These PCR products 
were ligated in the pcDNATM3.1 Directional TOPO® vector according to the protocol 
supplied by the manufacturer. After transformation in chemical competent E. coli. 
cells, positive clones were selected by restriction analysis and verified by 
sequencing.  
 
 
 
 
 
 
 
 
 
Fig. 4.8 Schematic representation of CB2-eCFP and CB2-eGFP expression constructs: Two 
essentially similar expression vectors under the control of a CMV promoter were generated. The CB2 
coding exon was fused with either eCFP (A) or eGFP (B). In order to optimize the expression efficacy, 
a Kozak sequence was added upstream of the CB2 start codon and a BGHpA - bovine growth 
hormone at the 3’-UTR. 
 
The CB2-eCFP and CB2-eGFP expression vectors contain a human cytomegalovirus 
virus (CMV) immediate early enhancer/promoter for high-level constitutive expression 
of the gene of interest in a wide range of heterologous proteins in most mammalian 
cells (Boshart, Weber et al. 1985; Nelson, Reynolds-Kohler et al. 1987; Andersson, 
M       1             2             3 
3 kb 
0.5 kb 
1 kb 
2 kb 
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Davis et al. 1989). Additionally, they have a neomycin resistance gene for the 
selection of stable cell lines using Geneticin®, G418 (Fig. 4.8). 
The control plasmid, pcDNATM3.1 Directional TOPO® served as a negative control 
and the pECFP-N1 or pEGFP-N1 plasmids, served as positive controls for 
transfection and expression in the mammalian cell line of choice. 
 
4.3.2 Western blot analysis of the CB2-eCFP fusion protein  
The CB2-eCFP and CB2-eGFP expression constructs were transfected in CHO-K1, 
HEK-293 and HeLa cell lines, that are commonly used for the functional analysis of 
GPCRs. Cells were selected for 3-4 weeks using the antibiotic G418. At the end of 
the selection process, single colonies were chosen and further cultured using G418 
containing cell culture medium. 
To verify the presence of the intact CB2-eCFP fusion protein, immunoprecipitation 
using an anti-GFP antibody (Abcam) was performed. About 2 mg of the total protein 
extract of CB2-eCFP cells was used.  
 
 
Fig. 4.9 Western blot analysis using a CHO cell extract: 2 mg of lysates from CHO cells, CB2, 
CB2-eCFP and eGFP expressing cells were used for immunoprecipitation with anti-GFP (ab290, 
abcam) antibody. The blot shows labeling of a 72 kD protein which is the expected molecular weight of 
CB2-eCFP fusion proteins (lane 1) and 27 kD for eCFP transfected cells (lane 3 - positive control). 
The CB2 control cell lysate shows no specific band (lane 2 - negative control).  
 
The theoretical calculated weight of murine CB2 receptor is 45 kD and for the eCFP 
protein 27 kD. Thus CB2-eCFP fusion will result in a 72 kD band (45 kD +27 kD). As 
expected, a major fusion band of 72 kD (Fig. 4.9) was observed, indicating that the 
full-length fusion protein was expressed in the CHO-K1 cells. Additionally a band 
corresponding to eCFP (27 kD) was also observed.  
 
72 kD 
CB2-eCFP fusion band 
27 kD 
eCFP band 
 1       2        3 
96 kD 
51 kD 
37 kD 
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4.3 3 Cellular expression of CB2-eCFP in different cell lines 
Since the CB2 receptor fusion resulted in a full-length expression of the fusion 
protein, I further wanted to analyze the cellular expression of this fusion receptor in 
cell lines. I had used 3 different cell lines, CHO-K1, HEK-293 and HeLa cell lines for 
this purpose.  Expression resulting from fluorescent analysis of the stably selected 
cell lines is shown in Fig. 4.10. 
 
 
Fig. 4.10 Cellular expression of CB2-eCFP: HEK-293 (A), CHO-K1 (B) and HeLa cells (C) 
transfected with CB2-eCFP show a localization of the fusion protein on the cell membrane (indicated 
by arrow) and intracellular (indicated by star). Scale bar = 20 µm. 
 
As shown above (Fig. 4.10), a strong fluorescence signal with CB2-eCFP fusion 
construct was obtained in HEK-293, HeLa and CHO-K1 cells. The fusion proteins 
CB2-eGFP and CB2-eCFP showed a similar subcellular expression pattern with a 
pronounced labelling of cell membranes. In most cells, an additional intracellular 
signal was obtained, suggesting a vesicular localization of CB2 receptors.  
4.3.4 Co-localization of CB2-eGFP with transferrin and ∝-giantin 
To verify the vesicular localization of fluorescent labelled CB2 receptors, CB2-eGFP 
expressing HEK-293 cells were incubated with Alexa-red-conjugated transferrin (TR). 
These cells were incubated with the cannabinoid receptor agonist HU-308 [100 nM] 
to stimulate the internalization of TR receptors (Xia, Kjaer et al. 2004). As shown in 
Fig. 4.11, a Co-localization of CB2-eGFP with the internalized TR receptors was 
observed, indicating an endosomal origin of the intracellular CB2-eGFP receptor 
fraction. To further determine the intracellular fluorescence origin, different markers 
such as Lamp I, Lim II (lysosomal markers), Calnexin (endoplasmic reticulum 
marker) and ∝-giantin (golgi marker) were used. Interestingly, the intracellular 
fluorescence signal was mainly colocalized with the golgi marker ∝-giantin.  
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Fig. 4.11 Co-localization of CB2-eGFP with transferrin and ∝-giantin: A) Cells were incubated for 
30 min with cannabinoid agonist HU-308 [100 nM] and Alexa red conjugated TR at 37°C. Cells were 
then fixed with 4% paraformaldehyde. The yellow fluorescence indicates a Co-localization of CB2-
eGFP (green) with internalized transferrin receptors (red) in endosomes. B) Cells were fixed, 
permeabilized and incubated with golgi marker, ∝-Giantin. Co-localization was observed as indicated 
by yellow fluorescence (D). Inlet: magnified view of the colocalisaton. Scale bar = 20 µm  
 
These data indicate that the CB2-eGFP protein was colocalized with transferrin and 
that the intracellular signal of the CB2-eGFP protein was largely restricted to a Golgi 
network.   
4.4 Functional investigation of the CB2-eCFP fusion protein 
To determine whether the CB2-eCFP fused receptor is still functional with respect to 
the downstream signaling pathway and agonist or antagonist mediated 
internalization, Erk-MAPK assays and internalization experiments were performed.  
 
4.4.1 MAPK assay in CB2 and CB2-eCFP expressing cells 
The ability of cannabinoids to regulate Erk-MAPK activity in the present cellular 
model was examined. A standard Western blot technique was used for studies. 
Serum starved cells were exposed to cannabinoid receptor agonists or antagonists 
and immediately proteins were isolated. The cellular proteins were seperated by SDS 
polyacrylamide gel electrophoresis. The relative amounts of active (phosphorylated) 
and total forms of Erk-MAPK in a given sample were analyzed by immunoblots 
performed with selective antibodies and quantified using an ImageJ software. 
No additional increase in the activation of Erk-MAPK in native CHO-K1 or HEK-293 
cells with or without the cannabinoid receptor agonist HU-308 or vehicle control 
DMSO under described experimental conditions was observed (data not shown). 
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4.4.2 MAPK activation in CB2-eCFP expressing HEK-293 cells 
As shown by Bouaboula et al. CB2 receptor transfected cells showed time-
dependent increase in levels of Erk-MAPK (Bouaboula, Dussossoy et al. 1999). I 
wanted to observe whether similar effects were seen in the CB2-eCFP cells. Thus, 
serum starved CB2-eCFP expressing HEK-293 cells were incubated with the 
cannabinoid receptor 2 agonist [10-8M] HU-308 for different time intervals. The levels 
of activated MAPK (phosphorylated form) and total MAPK were monitored after 5, 10, 
15, 20 and 30 min. The levels of active Erk-MAPK increased significantly within 15-
20 min of agonist incubation. After 30 min of incubation, the levels of the active Erk-
MAPK form began to decrease to basal levels (at 0th min) (Fig. 4.12). 
 
 
 
Fig. 4.12 Activation of Erk-MAPK in CB2-eCFP expressing HEK-293 cells: CB2-eCFP expressing 
HEK-293 cells were incubated with the CB2 agonist HU-308 [100 nM], for different time intervals. The 
level of activated Erk-MAPK was monitored in cells by using a pMAPK antibody (A). Total MAPK was 
detected by using an antibody directed against both activated and non-activated forms of MAPK (B). 
 
 
A time-dependent change of the phosphorylated Erk-MAPK form was observed in 
CB2-eCFP expressing HEK-293 cells incubated with the cannabinoid receptor 2 
agonist, HU 308, whereas the levels of total MAPK remained unaltered. Both HEK-
293 and CHO-K1 cells showed the Erk-MAPK activation in the presence of the 
cannabinoid receptor 2 agonist. HEK-293 cells under the experimental conditions 
used were easily detached from the surface. This resulted into a less number of cells 
available for assay and hence the less protein for the assay. Thus henceforth, I had 
used CHO-K1 cells for further Erk-MAPK assay. 
 
4.4.3 Direct comparison of CB2 and CB2-eCFP expressing CHO-K1 cell lines 
Similar to that of HEK-293 cells, I compared the downstream Erk-MAPK signaling 
activation in CB2 and CB2-eCFP expressing CHO-K1 cells.  
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Both cell lines were incubated for 15 min with increasing concentrations of the CB2 
receptor agonist, HU-308, and the level of Erk-MAPK was measured. In CB2 and 
CB2-eCFP expressing CHO-K1 cells, a concentration-dependent increase of 
phosphorylated Erk-MAPK levels was observed (Fig. 4.13).  
The level of activated Erk-MAPK was increased with 10-7 M HU-308 and reached the 
maximum at 10-5 M. However, the level of total Erk-MAPK remained unchanged. A 
difference in Erk-MAPK activation in CB2 and CB2-eCFP expressing cells was not 
observed (Fig. 4.13). I further wanted to examine the effect of CB2 antagonist on Erk-
MAPK activation in CB2 and CB2-eCFP cell lines. The antagonist treatment should 
result in the decrease of the Erk-MAPK phosphorylation upon treatment with the 
cannabiniod receptor agonist.  
A          B 
 
 
 
CB2 CHO cells     CB2-eCFP CHO cells 
C 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13 Erk-MAPK stimulation after HU-308 treatment: Activation of Erk-MAPK in CHO cells 
expressing CB2 (A)  and  CB2-eCFP (B) by incubation of CB2 agonist HU-308 for 15 min. The level of 
activated Erk-MAPK was monitored in cells using a pMAPK antibody. Total MAPK levels were 
measured by antibody detecting both activated and non-activated forms of MAPK. (C): Data obtained 
after densitometric analysis of signals for both CB2 and CB2-CFP cells is shown. MAPK-Erk 
phosphorylation is shown as the percentage of the maximal response occurring in the presence of 
increasing concentrations of the cannabinoid receptor agonist HU-308.   
CB2 and CB2-eCFP cells were treated with the cannabinoid receptor antagonist AM-
630 in presence or absence of HU-308 for 15 min. The level of MAPK-Erk activation 
was determined. As shown in Fig. 4.14, the level of Erk-MAPK was reduced by co-
p44        
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incubation with AM-630. No activation of Erk-MAPK in CB2 or CB2-eCFP cells 
treated with the cannabinoid receptor antagonist AM-630 or the vehicle control 
DMSO under the described experimental conditions was observed (data not shown). 
 
 
Fig. 4.14 Effect of cannabinoid receptor antagonist treatment on MAPK-Erk phosphorylation: 
CHO cells expressing (A) CB2-eCFP and (B) CB2 were incubated with CB2 agonist, HU-308 (HU) 
[100nM], with or without CB2 antagonist, AM-630 (AM) [1µM] for 15 min. The level of activated Erk-
MAPK was monitored in cells by using a pMAPK antibody. Total MAPK was detected by using 
antibody detecting both activated and non-activated forms of MAPK. C) Effect of antagonist: Data 
obtained after densitometric analysis of immuno-signals for both CB2 and CB2-eCFP in CHO-K1 cells 
is shown. MAPK-Erk phosphorylation was expressed in the percentage, taking the maximal response 
by the cannabinoid receptor agonist HU-308 (HU) as 100%. 
  
The extent of MAPK-Erk phosphorylation was equally observed in both CB2 and 
CB2-eCFP tagged CHO-K1 cells (Fig. 4.14). I could not detect any difference in the 
extent of MAPK-Erk phosphorylation after treatment with cannabinoid receptor 2 
agonist and antagonist in CB2 and CB2-eCFP cells. This led to the conclusion that 
the CB2-eCFP fusion protein exhibited no change in Erk-MAPK activation as 
compared to that of CB2 expressing CHO cells. 
 
4.5 Internalization of fluorescent tagged CB2 receptors 
Various G protein coupled receptors are shown to undergo receptor internalization 
after stimulation with the agonist. Cannabinoid receptor 1 also undergoes 
internalization after the stimulation with the agonists. Thus, I wanted to analyze the 
receptor mediated internalization in the stably transfected CB2-eCFP cell lines.   
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4.5.1 Effects of cannabinoid receptor agonists on internalization of CB2-eCFP 
in CHO-K1 cells 
 
In untreated CB2-eCFP CHO-K1 cells stably expressing murine CB2 receptors, the 
receptors were primarily localized on the cell membrane (Fig. 4.15 a). In many cells, 
a faint blush of intracellular staining was also observed; this represented staining of 
CB2 receptors in the Golgi network shown in Fig. 4.11. CHO-K1 cells were incubated 
with CB2 agonist HU-308 [100 nM] for 1 h with (D) or without CB2 antagonist AM-630 
[1µM] (B). 
 
 
 
 
Fig. 4.15 Internalization of fluorescent tagged CB2-eCFP receptors in CHO-K1 cells: CHO-K1 
cells were incubated with CB2 agonist HU-308 [100 nM] for 1 h with (D) or without CB2 antagonist 
AM-630 [1µM] (B). The cannabinoid receptor agonist HU-308 caused CB2 receptor internalization, 
which is blocked by the CB2 antagonist AM-630. (A) In unstimulated CB2-eCFP CHO-K1 cells stably 
expressing CB2 receptors, receptors were predominantly found on the plasma membrane (arrows). 
(B) After a 1 h treatment with the cannabimimetic [100 nM] HU-308 receptors internalized 
(arrowheads). (C) AM-630 alone did not caused any change in internalization. (D) Cotreatment with 
HU-308 and the CB2 receptor antagonist AM-630 blocked internalization with CB2 receptors 
remaining at the cell surface (arrows). Cells were stimulated with agonist alone or with antagonist for 1 
h in Hams F-12 medium containing 0.2 mg/ml bovine serum albumin at 37°C. Bar = 20 µm 
 
 
 
Following the treatment with the cannabinoid receptor agonist HU-308 [100 nM] for 1 
h at 37°C, most receptors were found inside the cell with a punctuated distribution 
(Fig. 4.15 b). Consistent with the CB2 receptor involvement, co-incubation of the CB2 
antagonist AM-630 [1µM] with HU-308 prevented receptor internalization (Fig. 4.15 
c). AM-630 treatment alone did not cause CB2 receptor internalization (Fig. 4.15 d). 
Cannabinoid agonists caused CB2-eCFP receptor internalization, which was blocked 
by the CB2 antagonist AM-630. 
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4.5.2 Effects of cannabinoid receptor agonists on internalization of CB2-eCFP 
in HEK-293 cells 
 
After establishing the internalization effects in CHO-K1 cells, I wanted to observe the 
internalization of the CB2-eCFP receptors after the treatment with different agonists 
in HEK-293 cells. HEK-293 cells expressing CB2-eCFP were incubated with [100 
nM] of the agonists HU-308, WIN 55,212-2 (Wotherspoon, Fox et al.) and HU-210 for 
5 min, 30 min and 1 h. The cannabinoid receptor agonists caused CB2 receptor 
internalization. As shown in Fig. 4.16, the cannabinoid receptor agonists HU-308, 
HU-210 caused more internalization as compared to the cannabinoid receptor 
agonist WIN. 
However, these cells show weak internalization effect after incubation with agonists 
in comparison with the reported internalization effects with CB1 receptor. With 
increase in time the CB2-eCFP receptors are internalized in HEK-293 cells (Fig. 
4.16). However, even without agonist treatment, some of the tagged cannabinoid 
receptors were internalized.  
 
Taken together, these observations with agonist treatment indicated that the CB2 
receptors do undergo internalization. Upon the treatment with the antagonist, CB2 
receptors appeared more prominently on the membrane.  
I had observed that eCFP fused cannabinoid receptor undergo internalization upon 
treatment with agonist and this is prevented by the antagonist treatment. These 
receptors also display unaltered downstream Erk-MAPK signaling. Thus C-terminal 
fusion of these receptors seems to unalter the functionality of these receptors. Based 
on this information I wanted to generate two similar constructs of CB2 protein namely 
CB2-eCFP and CB2-eGFP knock-in for the generation of fluorescent tagged mouse 
strains. 
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Fig. 4.16 Internalization of fluorescent tagged CB2-eCFP receptors in HEK-293 cells: HEK-293 
cells expressing CB2-eCFP were incubated with the cannabinoid receptor agonists HU 308, WIN and 
HU-210 at [100 nM] concentration for 5 min, 30 min and 1 h. The cannabinoid receptor agonists 
caused CB2 receptor internalization. (a) In unstimulated CB2-eCFP CHO cells stably expressing CB2 
receptors, receptors were predominantly found on the plasma membrane (arrows). After a 60 min 
treatment with the cannabinoid receptor agonists, receptors internalized (arrowheads). Cells were 
stimulated with agonists for 5 min, 30 min and 60 min in DMEM medium containing 0.2 mg/ml bovine 
serum albumin at 37°C. Bar=20 µm 
 
4.6 Generation of CB2-eCFP and CB2-eGFP knock-in mouse strains 
 
4.6.1 Targeting strategy of the CB2-eCFP knock-in mice 
The knock-in construct was designed such that it contains two homologous regions 
of CB2 sequence, termed as short arm and long arm. The short arm has a 1.5 kb 
homologous 5’ UTR region followed by the coding sequence of cannabinoid receptor 
gene fused with eCFP or eGFP sequence by a linker of six amino acids (GPVAT). 
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The fusion proteins generated from the corresponding knock-in alleles are essentially 
identical to those analyzed in the tissue cultures, except for the 5’-Kozak sequence 
which was not introduced. 
This was followed by a floxed neomycin gene and a 6.4 kb homologous 3´ UTR 
termed as long arm. Long arm sequence was followed by the HSV-TK cassette as 
shown in Fig. 4.17. 
  
 
Fig. 4.17 Targeting strategy for generation of CB2-eCFP knock-in mice: The CB2 exon, eGFP 
and the floxed neomycin cassettes are displayed as green, cyan, and grey boxes respectively. Upon 
homologous recombination, the resulting CB2-CFP-neo mice are bred to PGK-Cre transgenic animals 
in order to delete the floxed neo gene, thus resulting in the final CB2-CFP locus. P (red)- Southern 
probe, WT F and WT R - forward and reverse primers for the amplification of the wild type CB2 locus, 
KI R - reverse primer for the amplification of the CB2-CFP locus. 
 
4.6.2 Amplification of the 3´ and 5´ homology 
For the generation of the 3' homology (long arm), a fragment of 6.4 kb in 3´ UTR of 
the murine CB2 gene was amplified from 129/Sv genomic DNA by PCR. Apart from 
the genomic sequence additional Kpn I at 5´end, and Xma I restriction sites at 3´ end, 
were incorporated for further cloning procedures. The PCR product was purified by 
agarose gel extraction (Fig. 4.18). The amplified sequence was verified by 
sequencing reactions. This fragment was cloned into the pCR XL-TOPO vector, 
termed as 6.4 kb-CB2 pCR XL-TOPO vector. Clones with an insertion of the 
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sequence in 3´-5´ orientation were screened by restriction analysis, sequenced and 
used for further cloning steps.  
For the amplification of the 5' homology (short arm), a 2.5 kb region was amplified 
using ES cell genomic DNA of the 129/Sv mouse strain. Apart from the genomic 
sequence the primers contained additional Pac I and Age I restriction sites which 
were incorporated. The Pac I restriction site was incorporated for the linearization of 
the knock-in construct since it does not digest the short arm or the long arm. The 
PCR product was purified by agarose gel extraction and verified by sequencing 
reactions (Fig. 4.18). The amplified sequence was cloned into the pCR blunt II TOPO 
vector and termed as 2.5 kb-CB2 PCR blunt TOPO vector. Clones in 3´-5´ 
orientations were screened by restriction analysis and used further for cloning steps.  
 
 
Fig. 4.18 Gel electrophoresis of PCR products short and long arm: In each lane 3 µl of the 
appropriate PCR product was loaded and separated on a 1% agarose gel at 120 V. Lane M show 1 kb 
ladder (Invitrogen), lane 1 shows 2.5 kb CB2 short arm and lane 2 shows 6.4 kb long arm PCR 
fragments. 
 
Fusion step for CB2-eCFP fusion was described earlier in section 4.3.1. Resulting 
CB2-eCFP-N1 vector was digested with restriction enzyme Not I. A fragment 
containing 2.5 kb short arm was cloned into an exit vector, pPNT-M2 resulting vector 
was termed as CB2-short arm pPNT-M2 vector.   
A 6.4 kb long arm fragment from the 6.4kb-CB2 pCR XL-TOPO vector was cloned in 
by using Kpn I restriction site into CB2-short arm pPNT-M2 vector. The orientation 
was checked by the restriction analysis and then sequenced to verify the same. This 
resulted into a knock-in CB2-eCFP construct.  
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A similar targeting construct for the CB2-eGFP was generated using the pEGFP-N1 
vector in CB2 receptor fusion step. Fig. 4.18 represents two knock-in constructs used 
for the generation of knock-in mice. 
 
 
Fig. 4.19 Vector diagram for CB2-CFP and CB2-GFP knock-in constructs: Two similar constructs 
were generated containing CB2-eCFP or CB2-eGFP fusion proteins. These constructs contained 2.5 
kb of short arm followed by the eCFP or eGFP. Neomycin gene was floxed by loxP sites followed by a 
6.4 kb long arm. The vectors were lineralized with Pac I. The Ssp I and Hind III restriction sites were 
used for restriction analysis. 
 
4.6.3 Restriction analysis of the CB2-eCFP knock-in construct 
For the electroporations with knock-in constructs, clones were analyzed by restriction 
digestion with SspI and Hind III enzymes. The knock-in clone should result in 
fragments of 9.1, 4.8, 2.3 and 0.9 kb upon Ssp I digestion (Fig. 4.19). Similarly upon 
Hind III digestion knock-in clone should result in 9.3, 5.3, and 2.6 kb fragments. 
 
Fig. 4.20 Restriction analysis of CB2-eCFP knock-in construct: Knock-in construct was digested 
with SspI and Hind III restriction enzymes and fragments were analyzed by agarose electrophoresis. 
Lane 1 shows SspI, lane 2 show Hind III digested clone.  
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As seen in above Fig. 4.20, lanes 1 show fragments of 9.1, 4.8, 2.3 and 0.9 kb with 
Ssp I digestion. With Hind III digestion this clone showed 10.4, 4.2 and 2.6 kb 
fragments (lanes 2). This clone was further cultured, verified by sequencing, and 
used for the electroporations. 
 
4.7 Transfection of ES cells 
The targeting vectors were linearized with Pac I restriction enzyme and 
electroporated in ES cells. In total 11 electroporations were carried out in ES cells of 
R1 or MPI 2 origin. ES cells with a passage number between 15-18 were used for the 
electroporations. 
Tab. 4.2 Screening of knock-in ES cell clones: CB2-CFP-neo or CB2-GFP-neo 
knock-in constructs were electroporated in MPI2 or R1 ES cells. All together 1069 ES cells 
were screened with Southern blot analysis and 97 clones were tested positive for the 
homologous recombination (9%). 
 
As shown in Tab. 4.2, approximately 10-fold higher recombination frequency was 
observed with the MPI 2 ES cell line (11.9%) to that with R1 ES cell line (1.3%). 
 
4.8 Southern analysis of ES cells 
As shown in Tab. 4.3, a total of 1069 ES cells were screened by Southern blots for 
the homologous recombination. The Southern blot DIG probe of 406 bp was 
generated by PCR (Section 3.1.13). The probe binds to a sequence in the 3'-region 
of the CB2 gene (Fig. 4.17).  
 
Fig. 4.21 Southern blot analysis of ES cell clones: Lanes 1-5, marked with a box, represent the 
homologous recombinated ES cell clones. ES cell genomic DNA was digested with restriction enzyme 
XbaI. The DIG probe was used for the Southern screening. Lanes 6 -10 represents wild type ES cell 
clones. Recombinated clones show 2 bands of size 8.7 kb and 6.4 kb whereas wild type clones show 
a band of 6.4 kb. 
 
Construct ES cell origin No. of screened clones  
No. of positive 
clones 
CB2-CFP-neo MPI2 613 70 
CB2-CFP-neo R1 192 3 
CB2-GFP-neo MPI2 168 23 
CB2-GFP-neo R1 96 1 
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ES cell genomic DNA was digested with restriction enzyme XbaI. As shown in Fig. 
4.21, the homologously recombinant locus yielded two fragments of size 8.7 kb and 
6.4 kb whereas the wild type locus yielded only 6.4 kb fragment. 
 
 
4.9 Karyotypic evaluation of positively recombinant ES cells 
To determine the quality of homologous recombinated ES cells, karyotypic evaluation 
was performed. About 100 independent counts of homologous recombinated ES cell 
chromosomes were counted. In Fig. 4.22, a representative analysis used for counting 
is shown.  
 
Fig. 4.22 Representative graph for chromosomal number analysis of homologous 
recombinated ES cell clone: The karyotype measurement showing 65% of the ES cells showed 40 
chromosomal count. 
 
The karyogram analysis showed of 60-70% euploid cells, which indicated the 
recombinated ES cells were in good condition and could be used for the 
microinjection (Longo, Bygrave et al. 1997; Suzuki, Kamada et al. 1997). 
 
4.10 Generation of chimeric animals 
For the generation of CB2-eCFP chimeras, ten homologous recombinant ES cell 
clones were microinjected all together 26 times in blastocyts obtained from CD1 or 
C57BL/6J mice. The microinjections were performed by Juergen Schmidt and 
Charlotte Schick in the house of experimental therapy in Bonn (Tab. 4.3). 
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Construct ES cell origin Clones / No of   injections 
Germline 
transmission 
CB2-eCFP R1 3/6 1 
CB2-eGFP R1 ----- ---- 
CB2-eCFP MPI 4/8  
CB2-eGFP MPI 3/12 ---- 
  ∑10/26 1 
 
Tab. 4.3 Microinjections of the CB2-eCFP and CB2-eGFP knock-in constructs: 
CB2-eCFP or CB2-eGFP clones were microinjected in ES cells of MPI 2 or R1 origins. In all 
10, different ES cell clones were microinjected 26 times. The expected CB2-eCFP germ line 
transmission was seen in only one animal. 
  
After microinjection of CB2-eCFP and CB2-eGFP ES cell clones, different chimeric 
animals were born. Only one expected CB2-eCFP germ line transmission was 
obtained from the CB2-eCFP knock-in construct (Tab. 4.3). With the very similar 
CB2-eGFP knock-in construct, no germ line transmission was observed. 
 
 
Fig. 4.23 Chimeric animals that resulted from microinjection of the CB2-eCFP MPI2 ES cell 
clones: (A-D)These animals exhibited a chimeric percentage ranging from 10% to 70%. These mice 
were obtained by microinjection of MPI 2 clones in the C57BL/6J blastocysts. 
 
In Fig. 4.23 chimeric animals obtained from CB2-eCFP knock-in construct are shown. 
These animals show different chimeric percentage ranging from 5-70%. I had 
obtained 26 chimeric animals with CB2-eCFP knock-in construct of which 11 animals 
(8 male, 3 female) were of MPI2 background and 15 animals (11 male, 4 female) 
were of R1 background. With the similar knock-in construct of CB2-eGFP I had 
obtained 9 animals (6 male, 3 female) were of MPI2 background. 
 
4.11 Germ line transmission of the CB2-eCFP and CB2-eGFP allele 
Animals with a chimeric percentage more than 10% were mated to obtain germ line 
transmission of CB2-eCFP or CB2-eGFP allele. Chimeric animals obtained form MPI 
2 ES cell line were bred with the C57BL/6J female mice (black skin) and those from 
R1 ES cell background with the CD1 female mice (white skin). The progenies were 
visually analyzed for fur color.  
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Fig. 4.24 Chimeric animals that resulted from microinjection of the CB2-eCFP R1 ES cell clones 
and its germ line offspring: A) This animal was obtained by microinjection of R1 clone in CD1 
blastocysts. B) Germ line transmitted progeny obtained from the chimeric animal is shown. 
 
Until now only three germ line transmissions of CB2-eCFP-neo allele in R1 ES cell 
background were obtained; two of them were found to be of wild type origin and the 
gene of interest was transmitted only in one animal shown in Fig. 4.24.  
For the CB2-GFP-neo allele, three different homologous recombinated MPI 2 ES cell 
clones were injected into blastocysts. More than 15 chimeric animals were bred to 
obtain germ line transmission. No germ line transmission were yet obtained with the 
CB2-eGFP KI construct.  
 
4.11.1 Southern blot analysis of germ line transmission 
To test the genomic integration of the construct in mice, genomic DNA from the 
mouse tails was isolated and digested with Xba I. As shown in Fig. 4.17, the 
homologous recombinant locus yielded two fragments of 8.7 kb and 6.4 kb whereas 
the wild type locus yielded only a 6.4 kb fragment.  
 
Fig. 4.25 Southern blot verification mouse tail DNA for the germ line transmission: 
Representative Southern blot analysis of XbaI digested genomic DNA from mice carrying the CB2-
CFP-neo allele (lanes 4).  Lane 1-3 indicates wild type mice.  
 
As shown in Fig. 4.25, Southern blot analysis of genomic mouse tail DNA showed 
animal with the germ line transmission (lane 4), while the other animals only 
exhibited the wild type fragment. The heterozygous CB2-eCFP mouse was further 
bred to obtain homozygous animals. 
 
4.12 PGK-Cre recombination 
The heterozygous knock-in mice generated contained floxed neomycin cassette. This 
floxed cassette is directly located after the CB2-eCFP fusion protein and can 
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influence the stability and the expression of nearby genes. Thus to remove this, 
homozygous mice containing the CB2-eCFP-neo alleles were further bred with PGK-
Cre mice (Lallemand, Luria et al. 1998). PGK-Cre mice showed a ubiquitous 
expression of Cre recombinase, which acts on the loxP sequences within the CB2-
eCFP gene locus. After breeding CB2-eCFP homozygous knock-in animals with 
PGK-Cre mice, the neomycin cassette was ubiquitously removed in the resulting 
offspring, which were tested positive for the PGK-Cre sequence. Mice were 
genotyped by PCR. Heterozygous mice containing only CB2-eCFP allele were 
further bred to obtain homozygous mice. 
  
 
Genotype Total Males Females 
 Number % Total % 
of males 
Total % 
of females 
WT 24 30.7 13 33.3 13 33.3 
Heterozygous 36 46.1 17 43.5 17 48.7 
Homozygous 18 23 9 23 9 23 
Total 78  39 50 39 50 
 
Tab. 4.4 Representative table for generation of CB2-eCFP homozygous knock-in mice: 
Heterozygous mice were paired to generate homozygous mice.  
 
The mating chart of 4 heterozygous male mice with the 7 heterozygous female mice 
is summerized in Tab. 4.4. The percentage of male and female offsprings obtained 
after the pairing was found to be equal. The mating resulted in 23% of homozygous 
animals and about 46% of heterozygous animals. This indicates that transmission of 
knock-in gene in these mice followed Mendelian inheritance. 
 
4.13 Genotyping by CB2-eCFP mice with PCR 
Southern blot determination is time consuming, so to determine the genotype of the 
mice quick and easy PCR genotyping method was established (Section 1.1.16). The 
genomic DNA was obtained from tail biopsies (Truett, Heeger et al. 2000). The 
common forward primer binds in the coding region of the CB2 receptor whereas the 
wild type reverse primer binds at the 3´ region outside the coding region of the wild 
type locus and in the coding region of the eCFP or eGFP in knock-in locus (Fig. 
4.26).   
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Fig. 4.26 Schematic diagram showing an allele specific genotyping strategy for the CB2-eCFP 
mice: Forward common primer (Geno 1F) binds in the coding region of CB2 and wild type primer (WT 
3R) binds in the 3´ UTR. Knock-in primer (GFP 1R) binds in the eCFP coding region.   
 
The PCR analysis resulted in the amplification of different fragments for the (600 bp) 
and the CB2-CFP-neo allele (390 bp). PCR products were analyzed by gel 
electrophoresis as shown in Fig. 4.27. As expected the CB2-CFP-neo heterozygous 
locus yielded fragments of 600 bp and 390 bp and homozygous CB2-CFP-neo locus 
yielded only a 390 bp fragment.  Furthermore mice were tested for the presence of 
the PGK-Cre locus and for absence of neomycin by PCR. 
 
 
Fig. 4.27 Genotyping of CB2-eCFP knock-in animals: PCR analysis of genomic DNA from CB2-
eCFP knock-in mice after breeding to PGK-Cre. Lane 2, 4 indicate wild type mice, lanes 1, 3, 6, 7 
indicate heterozygous mice and lane 5 indicates homozygous mice.   
 
4.13.1 Southern verification for the deletion of neomycin gene 
After the breeding with the PGK-Cre mice, floxed neomycin cassette was removed 
which was verified by Southern blot analysis with the same DIG probe used for 
Southern screening of ES cells. The deleted locus will result in 7.1 kb fragment after 
digestion with Xba I enzyme.  Other GFP binding DIG probe will bind to the CB2-
eCFP region and should yield the same fragment of 7.1 kb size. Thus, genomic tail 
DNA from the offspring of CB2-eCFP knock-in mice and PGK-Cre mice was digested 
with XbaI. The Southern blots were screened with the DIG probe used previously for 
ES cell screening and GFP binding DIG probe.  
 
 
 
3`-UTR 
 WT 3R
5`-UTR
Geno1F 
exon 
loxPGeno1
5`-UTR Neo
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Fig. 4.28: Southern analysis of CB2-eCFP knock-in mice: Southern blot analysis of genomic tail 
DNA from CB2-eCFP knock-in mice after breeding to PGK-Cre where lane 4-7 indicates wild type 
mice, lane1 indicates heterozygous CB2-CFP-neo locus and lane 2 and 3 indicate homozygous CB2-
CFP locus after deletion of neo. Probed with CB2 probe (left) and GFP probe (right). 
 
As shown in Fig. 4.17, the homologous recombinant CB2-eCFP-neo allele yielded 
two fragments of 8.7 kb and 6.4 kb, whereas the wild type locus yielded only a 6.4 kb 
fragment. The homologous recombinant CB2-eCFP locus yielded a single fragment 
of 7.1 kb size. The results obtained were also verified with DIG probe binding in CFP 
coding region (Fig. 4.28). The results obtained from Southern blot analysis were in 
line with the PCR genotyping results.  The CB2-eCFP knock-in mouse line was 
established using these homozygous mice as founders. 
 
4.14 Expression analysis of homologous CB2-eCFP mice 
After obtaining CB2-eCFP knock-in mice, the protein expression and the 
fluorescence were investigated. In order to visualize the eCFP tagged fluorescent 
CB2 receptor, the homozygous CB2-eCFP mice were analyzed macroscopically, 
microscopically, by FACS analysis, by protein isolation and at mRNA expression 
level. 
 
4.14.1 Macroscopic visualization of CB2-eCFP 
The CB2 receptor is primarily expressed in the immune system. It is highly expressed 
in organs like the spleen, thymus and lymph nodes. Thus the spleen from the 
homozygous CB2-eCFP knock-in mice was removed and washed with PBS solution. 
Expression of CB2-eCFP protein was visualized directly in fresh organ by Leica 
macroscope.  eCFP fluorescence can be also visualized by using GFP filter set since 
the excitation and emission curve overlap with each other. Red filter observations 
were considered as a control for specific fluorescence (Fig. 4.29).    
  Results 
 
                                                  80
 
Fig. 4.29 Macroscopic visualization of spleen from CB2-eCFP and wild type mice: No specific 
eCFP fluorescence was seen in the spleen isolated from the homozygous mice (B) as compared to 
the wild type mice (A). Images a, b, g and h were taken at 1x magnification and d, e, i and j were taken 
at 2.5x magnification. 
 
No specific fluorescence could be observed in spleen from CB2-eCFP homozygous 
animals. Organs of wild type mice showed a similar unspecific fluorescence (Fig. 
4.29). Areas which showed green fluorescence also showed red fluorescence upon 
further observation with the red filter, indicating non specific fluorescence origin. 
This result showed that at the macroscopic level, there was no difference in 
fluorescence between wild type control and CB2-eCFP mice, implying no expression 
of CB2-eCFP protein.  
 
4.14.2 Microscopic visualization of CB2-eCFP 
In order to analyze CB2-eCFP expression at cellular level, microscopic visualization 
of the tagged CB2 receptors was performed. Animals were perfused with PFA and 
then organs were soaked in sucrose solution overnight. Cryosections were made 
from these tissues. Organs such as spleen, lymph nodes and thymus were examined 
for the specific eCFP fluorescence under the fluorescent microscope Axioplan 2 
imaging (Zeiss) as well as under Axiovert 40 CFL microscope (Zeiss) with specific 
eCFP filter set. Fig. 4.30 shows a representative spleen examination at different 
magnifications using a green filter for eCFP fluorescence visualization and a red filter 
for the non-specific fluorescence taken with Axioplan 2 imaging (Zeiss) microscope.  
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Fig. 4.30 Microscopic visualization of fluorescence in the spleen of CB2-eCFP and wild type 
mice: No eCFP specific fluorescence was seen in the spleen isolated from the homozygous CB2-
eCFP knock-in mice (B). Images a, b, c, g, h and i were taken at 10x magnification and d, e, f, j, k and 
i were taken at 40x magnification. Scale bar =100 µm 
 
As expected, wild type animals showed no significant signal for the eCFP (Fig.4.30 
A). The homozygous CB2-eCFP knock-in mice also exhibited no specific eCFP 
fluorescence (Fig.4.30 B). In cell culture experiments with eCFP transfected cells and 
CB2-eCFP transfected cells can be observed under GFP filter and they do not show 
fluorescence when red filter is used to visualize. Comparison of the unspecific 
fluorescence signals using the red filter indicated that there is no difference between 
wild type and CB2-eCFP knock-in mice organs. 
Spleen sections from wild type and CB2-eCFP knock-in homozygous animals were 
also visualized under the confocal microscope (Fig. 4.31). 
 
Fig. 4.31 Confocal visualization of spleens: Confocal images of a spleen of wild type (A) and CB2-
CFP knock-in homozygous mice (B) under water emulsion and 40x magnification. No eCFP specific 
fluorescence was observed in spleen sections of knock-in mice as compared to wild type animals. 
However, there was a significant amount of autofluorescence observed in spleen of wild type mice. 
Scale bar =100 µm 
 
However no specific fluorescence was observed in the CB2-eCFP knock-in 
homozygous spleen sections. Similarly no difference in thymus and lymph node 
sections was observed under confocal microscope. 
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4.14.3 FACS analysis of splenocytes from the CB2-eCFP knock-in mice 
FACS analysis is more sensitive as compared to the macroscopic or microscopic 
analysis. I considered the possibly weak signal of the CB2-eCFP protein resulting 
into no microscopic detection of the CB2-eCFP protein. These cells could be 
detected with the FACS analysis. Thus, I analyzed cells with FACS analysis for the 
fluorescence. Freshly isolated splenocytes from CB2-eCFP knock-in mice were 
analyzed by the LSR-II FACS (BioRad) (Fig. 4.32) with a specific blue laser for eCFP 
protein.  
 
Fig. 4.32 FACS analysis of splenocytes from homozygous CB2-eCFP knock-in mice: FACS 
analysis of CB2-eCFP splenocytes showed no detectable eCFP positive cell population were present 
in spleen of homozygous CB2-eCFP animals. A) Splenocytes from wild type animals B) Splenocytes 
from heterozygous CB2-CFP knock-in mice C) CB2-eCFP HEK cells as positive control. 
 
Unfortunately no specific fluorescence could be observed in the examined 
splenocytes (Fig 4.32,B). Similar observations were obtained when macrophages, 
thymus cells and lymph node cells analyzed by FACS analysis (data not shown). 
CB2-eCFP transfected HEK-293 cells, which were used as positive control, showed 
the population of the HEK-293 cells containing the fluorescent receptors (Fig 4.32,C).  
Wild type cells were used as a negative control (Fig 4.32,A).  
 
4.14.4 Expression analysis of CB2-eCFP at protein level 
Organs like spleen, thymus and lymph nodes from CB2-eCFP homozygous mice 
were lysed in protein lysis buffer and then fusion protein was immunoprecitated by 
using GFP antibody and detected with Western blot technique. 
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Fig. 4.33 CB2-eCFP protein expression analysis of CB2-eCFP mice: Immunoprecipitation of CB2-
eCFP fusion proteins detected by GFP antibody lymph nodes, thymus and spleen from wild type (WT) 
and CB2-eCFP homozygous (Homo) mice respectively. CHO-K1, CB2-eCFP transfected, positive 
control (+) and untransfected CHO-K1 as negative control (-). 
 
Western blot analysis showed no corresponding band for the fusion protein in the 
spleen, thymus and lymph nodes from CB2-eCFP knock-in homozygous animals 
(Fig. 4.33). Native HEK-293 cells and cells transfected with CB2-eCFP were used as 
positive and negative controls. A very weak band of 72 kD in lymph nodes was 
observed. However fluorescent expression analysis could not indicate any specific 
fluorescence in these organs. 
Taken together, macroscopic, microscopic visualization, immuno precipitation results, 
and FACS analysis of CB2-eCFP expression displayed no specific signals of the 
fluorescence protein in the knock-in animals. Next, I wanted to determine whether the 
CB2-eCFP fusion transcript was expressed in these knock-in mice. 
 
4.14.5 Detection of the CB2-eCFP fusion transcript by mRNA expression 
analysis. 
Total RNA (tRNA) was isolated from spleen and thymus of wild type, homozygous 
and heterozygous CB2-eCFP knock-in mice. To avoid DNA contamination, tRNA was 
followed by additional DNAse digestion step. Further tRNA was analyzed by RT-PCR 
for expression of CB2-eCFP transcript.  
 
Fig. 4.34 Expression analysis of CB2-eCFP transcript: Allele specific semi quantitative RT-PCR 
analysis of cDNA from spleen and thymus tissue of wild type mice (WT) (lane 1,2), heterozygous 
(hetero) (lane 3,4) and homozygous (homo) (lane 5,6) CB2-CFP knock-in mice, respectively. 
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Gel electrophoresis of the RT-PCR analysis demonstrated that the CB2-CFP 
transcript was present in the spleen and thymus of heterozygous (Fig. 4.34, lane 3, 
4) as well as in the homozygous mice in spleen and thymus (Fig. 4.34, lane 5,6). In 
the spleen and thymus of wild type control animals, only the CB2 transcript was 
observed (Fig. 4.34, lane 1, 2). 
Although CB2-CFP protein was not detected in macroscopic and microscopic 
analysis, mRNA analysis for the expression of CB2-eCFP in homozygous and 
heterozygous CB2-eCFP knock-in animals using the allele specific primers revealed 
that the fusion transcript is present in spleen, thymus (Fig. 4.34) and in lymph nodes 
(data not shown) of these animals.  One possibility could be the levels of CB2 are 
much below the detection levels. Thus models where CB2 expression is known to be 
highly up regulated may result in detection of CB2-eCFP protein. 
The cannabinoid receptor 2 is reported to be highly up regulated in animal model 
systems such as, contact hypersensitivity (Karsak, Gaffal et al. 2007) and neuropathy 
pain model (data unpublished). Thus I used these systems where the CB2 
expression was up regulated and possibly that increase in expression resulting into a 
detectable CB2-eCFP fluorescence.  
 
4.14.6 Contact hypersensitivity model in CB2-eCFP knock-in mice 
In the cutaneous contact hypersensitivity model, mice were challenged with the 
contact allergen DNFB to induce allergic response. Wild type and homozygous CB2-
eCFP knock-in mice were treated with DNFB and the ear swelling was measured 
after the second challenge (Fig. 4.35). 
 
 
Fig. 4.35 Ear swelling in wild type and homozygous CB2-eCFP knock-in mice: Graph shows ear 
swelling after the second challenge with DNFB. Equal extents of ear swelling were observed in wild 
type (WT) and homozygous animals (CB2-eCFP). 
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I observed an increase in the ear swelling in wild type and CB2-eCFP knock-in mice 
after treatment with DNFB. The extent of ear swelling was not different in the two 
examined mouse strains, indicating that CB2-eCFP knock-in mice showed no altered 
allergic reaction in this contact hypersensitivity model. After the DNFB treatment mice 
were perfused with PFA and the DNFB treated ears were removed and additionally 
fixed with 4% PFA for 2 h. Ears were soaked in 30% sucrose solution over night 
before cryo sections were made and visualized for the CB2-eCFP fluorescence 
under Axioplan 2 imaging microscope (Zeiss).  
 
 
 
Fig. 4.36 Histological analysis of DNFB treated ears of CB2-eCFP and wild type mice: A) After 
the CHS was induced sections of ears of wild type and CB2-eCFP knock-in mice were observed under 
fluorescence microscope. B) Phase contrast images of the ears of wild type and CB2-eCFP knock-in 
mice. No specific fluorescence was observed in the sections of ears of homozygous animals after 
CHS. Scale bar =100 µm 
 
No specific fluorescence was seen in the ears of the CB2-eCFP knock-in 
homozygous animals as compared to the wild type ears (Fig. 4.36).  
 
4.14.7 Neuropathy pain model 
A second known model used in our lab, where CB2 expression is up regulated, is the 
neuropathy pain model. In this model a neuropathic pain is induced by a partial 
sciatic ligation of nerve. This results in up regulation of CB2 expression in spinal cord 
region (data unpublished). The homologous CB2-eCFP knock-in and wild type mice 
were operated for a partial ligation. One week after surgery, the mice were sacrificed 
to examine the expression of CB2-eCFP. The spinal cord was removed and fixed 
with 4% PFA followed by 30% sucrose treatment before cryosections were made. 
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These sections were then observed for CB2-eCFP fluorescence under fluorescence 
microscope (Axioplan 2, Zeiss). 
A punctuated green fluorescence pattern was seen (Fig. 4.37 A). Unfortunately this 
punctuated pattern was similar to that observed with the red filter, indicating non-
specific fluorescence (Fig. 4.37 B). Moreover similar pattern was also present in wild 
type mice confirming the nonspecific origin (data not shown). 
 
 
 
Fig. 4.37 CB2-eCFP expression in the neuropathy pain model: Spinal cord sections were analyzed 
by the fluorescence microscope. Spinal cord sections of 12 µm were studied with GFP (a) and red 
filters (b). No specific fluorescence was observed. Scale bar =50 µm 
 
I have generated a CB2-eCFP knock-in mice and the expression of CB2-eCFP from 
these mice were analyzed macroscopically, microscopically, by FACS analysis and 
by protein immunoprecipitation. Unfortunately no protein expression was seen. 
However, CB2-eCFP transcript was present as detected by RT-PCR analysis. In 
models where CB2 expression is known to be up regulated also failed to detect the 
specific CB2-eCFP fluorescence. 
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5 Discussion 
During the last decade, interest in the potential medicinal use of cannabinoid drugs 
has greatly increased. The endocannabinoid system performs various regulatory 
functions and has been implicated in a growing number of physiological roles, both in 
the central and peripheral nervous systems and in peripheral organs (Klein, Newton 
et al. 2001; Howlett, Barth et al. 2002; Mechoulam, Spatz et al. 2002; Howlett 2005). 
To complement the pharmacological analysis of the cannabinoid system, our group 
and other researchers use a genetic approach such as targeted deletions of 
cannabinoid receptor genes CB1 (Ledent, Valverde et al. 1999; Zimmer, Zimmer et 
al. 1999; Marsicano, Wotjak et al. 2002; Robbe, Kopf et al. 2002), and CB2 (Buckley, 
McCoy et al. 2000) in mice.  
Our group has also generated CB1-CB2 receptor double knock-out mice. Strikingly, 
these mice show severe wounds near metallic ear clippings (Fig. 4.1). These animals 
also scratch there ears more often compared to wild type animals. Cannabinoids 
exhibit immunomodulatory properties that influence several components of the 
immune-response machinery (Schatz, Lee et al. 1997; Berdyshev 2000). Moreover, 
previous work indicated that endocannabinoids promote wound closure in human 
colon injury (Wright, Rooney et al. 2005). In this study, the cannabinoid agonists, 
anandamide (AEA), noladin ether (NE) and arachidonylcyclopropyllamide (ACPA), 
showed increase in wound closure in in vitro scratch assay with human colonic 
epithelial cell lines, HT29 and DLD1. Cannabinoids have also shown to play a 
protective role in brain (Biegon and Joseph 1995; Panikashvili, Simeonidou et al. 
2001; Mechoulam, Spatz et al. 2002; Kreutz, Koch et al. 2007), cardiac (Lagneux and 
Lamontagne 2001), ocular (Lalonde, Jollimore et al. 2006) ,liver (Julien, Grenard et 
al. 2005; Batkai, Osei-Hyiaman et al. 2007; Mallat, Teixeira-Clerc et al. 2007) injuries.  
These studies and our observations prompted us to address the possibility of 
impaired wound healing in the cannabinoid receptor double knock-out animals. To 
investigate the role of these receptors in wound healing, full thickness excision 
wound healing model was employed (Werner, Smola et al. 1994; Werner and Grose 
2003). This model can be used to evaluate the ability of keratinocytes to stimulate 
wound healing. Keratinocytes synthesize numerous growth factors and cytokines that 
can influence wound healing. Keratinocytes are known to express CB1 receptors 
(Maccarrone, Di Rienzo et al. 2003). Both the CB1 and CB2 receptors are expressed 
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in normal epidermis and skin tumours of mice and humans (Casanova, Blazquez et 
al. 2003), as well as, shown to be expressed on sensory nerve fibres and adnexal 
structures in human skin (Stander, Schmelz et al. 2005). However, CB2 expression 
in these cells has been also debated (Ibrahim, Porreca et al. 2005; Oka, Wakui et al. 
2006). Absence of these receptors in knock-out animals may lead to imbalance in 
regulation of endocannabinoid system and thus may result in wound impairment 
phenoytype in knock-out animals. 
Wound healing is a natural process which involves regeneration of dermal and 
epidermal tissue. This complex process can be artificially categorized into three 
overlapping phases inflammatory, proliferative, and remodelling phase (Stadelmann, 
Digenis et al. 1998; Stadelmann, Digenis et al. 1998; Iba, Shibata et al. 2004). In 
mice inflammatory phase occurs within first 3 days where invasion of inflammatory 
cells, secretion of various inflammatory cytokines around site of injury takes place 
(Werner and Grose 2003). This is followed by proliferating phase (3-5 days) and 
finally leading to remodelling phase (5 day onwards) where activation of matrix 
metalloproteases (Pilcher, Wang et al. 1999; Wilson, Ouellette et al. 1999), secretion 
of various growth factors, migration of fibroblasts and keratinocytes, angiogenesis, 
wound contraction and finally remodelling of the scar tissue takes place (Martin 
1997). Cannabinoid receptors and cannabinoids has been shown to influence 
migration of various immune related cells (Schatz, Lee et al. 1997; Berdyshev 2000; 
Jorda, Verbakel et al. 2002; Gokoh, Kishimoto et al. 2005; Ghosh, Preet et al. 2006). 
Thus I expected altered immune modulatory response in knock-out animals which 
might lead to observed phenotype. Therefore, I analyzed the wound healing in these 
mice on 5th day and 13th day. These double knock-out animals were of mixed genetic 
backgrounds of C57BL/6J and 129/Sv. I had also included single knock-out animals 
of C57BL/6J background with their control animals of C57BL/6J background. 
However, no change in the wound healing properties in cannabinoid knock-out 
animals as compared to the wild type control animals was observed (Tab. 4.1 and 
Fig. 4.2), indicating that observed lesions are not due to impaired wound healing.  
The phenotype was also lost when pure brass tags were used instead of high nickel 
tags. Alterations in tissue architecture, infiltration of mast cells, swelling of regional 
preauricular and submental lymph nodes in double knock-out mice showing wounds 
hinted towards an altered allergic response in these animals thus a cutaneous 
hypersensitivity model was further investigated (Karsak, Gaffal et al. 2007). 
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5.1 Role of cannabinoid system in contact hypersensitivity (CHS) 
In this model system, we examined the possible involvement of cannabinoid 
receptors and its ligands in DNFB induced hypersensitivity. We found that upon 
repeated treatment with allergen DNFB, which induces a specific T-cell mediated 
allergic response, resulted in a remarked increase in the ear swelling in CB1/CB2 
double knock-out mice (Fig. 4.3 A). Upon further investigations, we noted similar ear 
swellings were also observed in CB1 and CB2 single knock-outs (Fig. 4.3 B). This 
suggests a nonredundant role for each cannabinoid receptor in the allergic response 
to DNFB. This would also suggest that milder response originating from ear tags was 
only observed in mice lacking both receptors.  The genetic blockade of the 
cannabinoid receptors resulted in allergic response. Further we examined the effect 
of pharmacological blockade using cannabinoid receptor antagonists on wild type 
mice after inducing DNFB induced CHS. We found upon subcutaneous treatment 
with these antagonists ear swelling was increased (Fig. 4.3 C). This further supports 
our assumption that endocannabinoid system is involved in the DNFB induced CHS. 
Studies by Ueda et al. reported effects of the CB2 receptor antagonists JTE-907 and 
SR144528 upon repeated topical application of DNFB on BALB/c female mice ear 
provoked ear swelling from 24 h after the 2nd application. These authors also 
reported significant and dose dependent inhibition of ear swelling upon acute oral 
administration of cannabinoid antagonists once a day for 6 days before and 1 and 23 
h after the 4th exposure to DNFB (Ueda, Miyagawa et al. 2005). This suggests that 
CB2 antagonism may be initially beneficial but detrimental upon chronic blockade. 
Thus both the pharmacological blockade as well as genetic blockade proved the role 
of these individual receptors in contact hypersensitivity. 
We observed upregulation of CB2 mRNA after DNFB treatment (Karsak, Gaffal et al. 
2007). Similar increase in CB2 mRNA was also observed after DNFB treatment in 
mouse ears by Ueda et al. supporting our observations (Ueda, Miyagawa et al. 2005; 
Ueda, Miyagawa et al. 2007). We also observed increase in the AEA and 2-AG levels 
after DNFB treatment in wild type and double knock-out animals which was more 
pronounced in later (Karsak, Gaffal et al. 2007). Similar increase in the 
endocannabinoid 2-AG was observed in another model system where 12-O-
tetradecanoylphorbol 13-acetate (TPA) was used to induced acute inflammation in 
mouse ear (Oka, Wakui et al. 2006). These observations strongly indicate that 
endocannabinoid system is regulated in case of inflammation. It is possible, 
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therefore, that the involvement of the cannabinoid system is a common feature of 
inflammatory reactions.  
Several investigators demonstrated that cannabinoids and the CB2 receptor exert 
suppressive effects on the inflammatory reactions and immune responses (Gokoh, 
Kishimoto et al. 2005; Gokoh, Kishimoto et al. 2005; Kishimoto, Muramatsu et al. 
2005). For example, in rat peripherally administered cannabinoids inhibited 
carrageenan-induced edema, thermal hyperalgesia, and decrease in capsaicin 
induced edema and plasma extravazation (Richardson, Kilo et al. 1998). 
In this study we also found that the topical and subcutaneous application of the Δ9-
THC reduced ear swellings induced by DNFB treatment (Fig. 4.4). Similarly ear 
swelling induced by TPA was also reduced upon Δ9-THC treatment (Oka, 
Yanagimoto et al. 2005). Together these studies support the idea that the activation 
of endocannabinoid system may function to dampen the inflammatory response. In 
contrast, the specific CB2 receptor agonist HU-308 showed either no efficacy after 
s.c. application (Fig. 4.4 A) or even increased the allergic response after topical 
application (Fig. 4. 4 B). It has recently been shown that the CB2 receptor inverse 
agonist Sch.336 inhibits leukocyte chemotaxis and thus, HU-308 administration to 
the inflamed ear may have further increased leukocyte infiltration leading to more 
pronounced inflammatory response and might have resulted in increase in swelling 
(Lunn, Fine et al. 2006). 
This opens up new avenues to treat the allergic diseases in humans like allergic 
contact dermatitis, which affects about 5% of men and 11% of woman in 
industrialized countries and is one of the leading causes for occupational diseases 
(Karsak, Gaffal et al. 2007). CHS is an inflammatory skin disorder associated with an 
itch. It has been reported in the human clinical studies that topical endocannabinoid 
application causes decrease in severity of itch (Szepietowski, Szepietowski et al. 
2005; Stander, Reinhardt et al. 2006). To study exact mechanism of these processes 
and the role of cannabinoid receptors in in vivo system, it would be helpful to have 
mice model where distribution of these receptors can be easily analyzed. 
However, we and other colleagues commonly encounter non- specific CB2 immuno-
staining using cannabinoid receptor knock-out animals due to the scarcity of 
commercially available CB2 antibodies with substantial and/or authentic 
immunoreactivity. In addition to this problem, when compared to the relatively high 
expression of CB1 in the brain (≥ 1 pmol/mg) (Abood, Ditto et al. 1997), CB2 
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expression in immune cells or immune tissues is more moderate (10–300 fmol/mg 
(Gonsiorek, Fan et al. 2007). Thus, to overcome the technical difficulties in CB2 
receptor detection, I wanted to generate a knock-in mouse strain where the CB2 
receptor is tagged with the eCFP or eGFP protein, so that the CB2 receptor can be 
easily visualized and well studied.  
Here, I report the generation of a novel CB2-eCFP and CB2-eGFP knock-in reporter 
mouse, which was aimed to allow the identification and isolation of viable fluorescent 
tagged CB2 receptor expressing cells in vivo and in vitro. Live cell observation 
potentiates a new type of experiment not previously possible using conventional 
techniques in which cells were required to be fixed prior to the visualization. This 
mouse would represent a useful tool to study various pathological conditions, where 
CB2 is involved.  In addition, this fluorescent reporter system will also aid studies to 
understand the role of CB2 receptors in various tissues where the role of CB2 is still 
unknown or need to be elucidated.  Therefore, I wanted to generate the tagged CB2 
receptors, characterize them in in vitro and based on this generate knock-in mice 
expressing similar fusion.  
 
5.2 Generation of fluorescent tagged CB2 knock-in mice  
To allow direct visualization of the CB2 receptors, in this work eGFP and eCFP 
fluorescent tagged CB2 receptor were generated. Such fusion proteins are widely 
used to study protein trafficking (Lippincott-Schwartz and Smith 1997), and their 
usefulness is amply demonstrated  for GPCRs (Kallal and Benovic 2000; Daly and 
McGrath 2003).  
Expression of functional cannabinoid receptor 2 with C-terminal eGFP fusion has 
been reported in bone marrow and in the myeloid (32D/G-CSF-R) cells. The 
functionality of CB2-eGFP fusion in these cells was validated by assaying 2-AG 
induced transwell migration (Jorda, Lowenberg et al. 2003; Alberich Jorda, Rayman 
et al. 2004). Similarly, in neuroblastoma cells, C-terminal fusions with cannabinoid 
receptors (FLAG-CB1-IRES-EGFP and FLAG-CB2-IRES-EGFP retroviral construct) 
were successfully used in cAMP assay (Ishii and Chun 2002). Additionally, it has 
been shown that cannabinoid receptor 1 with similar C-terminal GFP fusion 
undergoes constitutive internalization and trafficking (Leterrier, Bonnard et al. 2004; 
Leterrier, Laine et al. 2006). Thus, I expected an unaltered functionality of the CB2 
receptor after C-terminal fusion with eGFP or eCFP proteins. However, previous 
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studies with other receptors have reported that the C-terminal is important for 
receptor trafficking (Smyth, Austin et al. 2000). The truncation of the C-terminal may 
alter the tertiary structure of the receptor in a manner that changes its cellular 
trafficking, or specific determinants of the receptor sequestration. For example, 
mutation of a dileucine motif located in the C-terminal of the adrenergic receptor 
inhibits agonist-induced sequestration (Gabilondo, Hegler et al. 1997), but does not 
alter agonist-induced internalization of the thromboxane receptor (Parent, Labrecque 
et al. 1999; Parent, Labrecque et al. 2001). Thus, it is important to characterize the 
generated fusion protein.  
In this study, I have established an in vitro expression system, based on C-terminal 
GFP and CFP fusion of CB2 receptors expressed in CHO-K1, HEK-293 and HeLa 
cell lines. Since CHO-K1 cells do not express endogenous CB2 receptors 
(Bouaboula, Desnoyer et al. 1999), this cell line have been commonly used for 
studying overexpressed cannabinoid receptors along with the CB2 expressing HEK-
293 (NM_001841) and HeLa cell lines. This indicates the presence of a functional 
signalling cascade in the downstream pathways of the CB2 including several G 
protein alpha subunits (G alpha i/o) that are important for CB2 mediated response 
resulting in adenylate cyclase inhibition and phospholipase C activation. Thus these 
cells can be used as model system. Microscopic examination revealed predominant 
intracellular as well as plasma membrane localization of the CB2-eGFP or CB2-
eCFP receptors (Fig. 4.10). Similar fluorescent expression pattern was observed by 
us (data unpublished) and by others with eGFP tagged CB1 receptor (Leterrier, 
Bonnard et al. 2004; Leterrier, Laine et al. 2006). Leterrier et al. have also reported 
that in CB1-eGFP HEK cells co-overexpressing angiotensin II AT1A and 
somatostatin SSTR2 receptors showed the same levels of transfected receptors with 
a predominant plasma membrane localization (Miserey-Lenkei, Lenkei et al. 2001), 
indicating that overexpression was not the cause for intracellular receptor 
accumulation. 
 A similar observation, of predominant intracellular and weak plasma membrane 
expression, was obtained in cell lines other than HEK-293, such as CHO-K1 and 
HeLa cells (Fig 4.10). Using a confocal microscope, it was observed that these 
receptors were also colocalized with the plasma membrane marker transferrin 
receptors (Fig 4.11 A). Transferrin receptor is found to be localized within lipid rafts 
and CB1 receptor has been shown to colocalize with it (Leterrier, Bonnard et al. 
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2004). It would be therefore interesting to study if CB2 receptor is also present within 
the lipid rafts. However, recently Bari et al. showed that in immune cells and neuronal 
cells only CB1 receptor signalling is controlled by lipid rafts, but not that of CB2 
receptor (Bari, Spagnuolo et al. 2006; DeMorrow, Glaser et al. 2007). In order to find 
the origin of the strong intracellular signal different organelle markers were used. 
Only with α-giantin, which is a golgi marker, a complete interacellular Co-localization 
was observed (Fig. 4.11 B). This confirmed juxtanuclear subcellular distribution of 
CB2-eCFP fusion protein within golgi compartment. Cannabinoid receptors are 
known to undergo glycosylation (Song and Howlett 1995; Gonsiorek, Fan et al. 
2007), which predominantly takes place in golgi apparatus. Golgi is also the site of 
receptor dephosphorylation and/or dissociation of the receptor/ligand/-arrestin 
complex to deliver a resensitized receptor to the cell surface for various other GPCRs 
(Zhang, Ferguson et al. 1996; Cornea, Janovick et al. 1999; Anborgh, Seachrist et al. 
2000). Thus, it is not surprising that CB2 receptors are highly colocalized with a golgi 
marker.  
 
Further, I wanted to detect the expression of intact fusion protein in this 
overexpression system. Theoretical calculated CB2 size is 45 kD and that of the 
fused eCFP or eGFP fluorescent proteins is 27 kD, thus fusion should result in CB2-
eCFP or CB2-eGFP band of 45 kD + 27 kD that is of 72 kD size. I used anti-GFP 
antibody (Toyota, Shimamura et al. 2002; Gupta, Proia et al. 2007; Tsang, Chan et 
al. 2007) to test whether the complete CB2-fusion protein is expressed in cell culture 
system. As expected the anti-GFP antibody recognized a major diffuse 72 KD protein 
and an additional but defined 27 kD protein in the CB2-transfected (but not parental) 
CHO cells (Fig. 4.19). The appearance and size of these proteins was consistent with 
the predicted size for the C-terminal fusion for the CB2. Additionally, the faint 27 kD 
band may be due to the degradation of the fusion receptor since the band migrates at 
the similar distance to that expected for native GFP protein (Fig. 4.9).  
The major diffuse appearance of the 72 kD receptor protein is consistent with the 
migration patterns of a glycoprotein (Hipkin, Sanchez-Yague et al. 1992; Gu and 
Schonbrunn 1997). The classification of CB2 as a glycoprotein was verified by its 
successful purification with wheat germ agglutinin chromatography prior to Western 
blot analysis (Gonsiorek, Fan et al. 2007). A minor band corresponding to a 
molecular weight of approximately 70 kD was observed, which could represent a 
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degraded receptor or another form of the receptor. Supporting observations were 
reported in studies by Carayon et al. and Gonsiorek et al. with transfected human 
HA-tagged CB2 receptor (Carayon, Marchand et al. 1998; Gonsiorek, Fan et al. 
2007).  
Next, I have also attempted to detect the fusion protein by using anti-CB2 antibody 
(Cayman chemical) for the re-verification of presence of 72 kD CB2 fusion protein. I 
had used spleen and brain tissue lysates from CB2 knock-out animal as negative 
control.  However, I found a nonspecific CB2 band which was even present in protein 
lysates from brain as well as from spleen of CB2 knock-out mice (data not shown) 
showing nonspecificity of the CB2 antibody. Similar unsuccessful CB2 receptor 
detection attempts were also reported by a study in which various anti-CB2 
antibodies (Calbiochem 209552 and 209554, ABR PA1–744 and PA1–746, Alexis) 
were tested using a panel of recombinant and tumour cell lines. The immunoreactive 
protein(s) were either too small or too large and/or were equally evident in samples 
from cells that do express CB2 (Gonsiorek, Fan et al. 2007). In this study 
immunoreactive bands were quite sharp, inconsistent with expected CB2 size 
(Hipkin, Sanchez-Yague et al. 1992; Gu and Schonbrunn 1997; Hipkin, Friedman et 
al. 1997). Taken together, these data indicate that CB2 antibodies are less than 
optimal for the immunodetection of authentic CB2 receptor (Gonsiorek, Fan et al. 
2007).  
After verifying the correct size of the fusion protein, I wanted to compare the 
functionality of the fusion protein to that of the native CB2 protein. I used CB2 
receptor downstream signalling Erk-MAPK assay and internalization experiments to 
examine functionality of CB2 fused proteins. 
MAP kinases, also known as extracellular signal-regulated kinases (Erks), act as an 
integration point for multiple biochemical signals, and are involved in a wide variety of 
cellular processes such as proliferation (Moniz, Verissimo et al. 2007; Wang, Lu et al. 
2007), differentiation (Matsumoto, Hatanaka et al. 2006; Ge, Xiao et al. 2007), 
transcription regulation (Fitsialos, Chassot et al. 2007; Salim, Standifer et al. 2007) 
development (Fata, Mori et al. 2007; Scholl, Dumesic et al. 2007) and 
immunomodulation (Zhao, He et al. 2005). Many studies showed that the Erk-MAPK 
pathway is activated upon cannabinoid agonist stimulations mediated by both CB1 
(Rubino, Vigano et al. 2006; Corbille, Valjent et al. 2007) and CB2 receptors 
(Bouaboula, Poinot-Chazel et al. 1996; Bouaboula, Dussossoy et al. 1999; 
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Shoemaker, Ruckle et al. 2005). 
I compared the extent of agonist dependent phosphorylation of Erk-MAPK signalling 
pathway using CB2-eCFP and CB2 expression construct. I had also observed HU-
308 concentration dependent Erk-MAPK´s activation in CB2 and CB2-eCFP tagged 
receptors (Fig. 4.13). Similar concentration dependent Erk-MAPK activation was 
observed by Shoemacker et aI. in CB2 expressing CHO cells with cannabinoid 
agonist, CP55,940 (Shoemaker, Ruckle et al. 2005). I also studied the time 
dependent Erk-MAPK phosphorylation (Fig. 4.12) which was similar to that reported 
by Bouaboula et al. (Bouaboula, Poinot-Chazel et al. 1996). On the other hand, co-
incubation with CB2 receptor antagonist AM-630 showed an equal decrease in Erk-
MAPK activation state in both native and fused cells (Fig. 4.14). Thus the fusion 
protein showed as expected similar downstream MAPK signalling response.  
After determining the unaltered functionality in downstream MAPK signalling, I 
wanted to observe internalization of the CB2-eCFP receptors. Compared to the large 
amount of information that has been gathered regarding the mechanisms of 
endocytosis and downregulation of other GPCRs, the knowledge on the routes and 
mechanisms of cannabinoid receptor endocytosis is still limited. Similar to that 
observed in case of other GPCRs (Ferguson 2001), CB1 is shown to be 
desensitized/internalized after binding with the ligand and again after the 
dephosphorylation step it can be trafficked back to the cellular membrane (Hsieh, 
Brown et al. 1999; Leterrier, Bonnard et al. 2004; Leterrier, Laine et al. 2006). This 
regulates the availability of the receptor on the membrane and hence the receptor-
mediated action is tightly regulated. It has been shown that CB1 receptors undergo 
rapid internalization after activation with various cannabinoids like WIN 55,940, CP 
55,940, HU-210. (Hsieh, Brown et al. 1999; Jin, Brown et al. 1999; Roche, Bounds et 
al. 1999; Coutts, Anavi-Goffer et al. 2001; Berghuis, Rajnicek et al. 2007). Also for 
the human CB2 receptor, Ser 352 phosphorylation dependent internalization has 
been put forth (Bouaboula, Desnoyer et al. 1999; Bouaboula, Dussossoy et al. 1999). 
However, the exact mechanisms underlying these phenomena have not yet been 
elucidated.  
I studied in CB2-CFP expressing CHO-K1 cells, effects on internalization upon 
treatment with the cannabinoid receptor agonist HU-308. These cells showed 
internalization upon incubation with HU-308 and this can be reversed by the use of 
the cannabinoid receptor 2 antagonist AM-630 (Fig. 4.15). However, I could not 
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observe a rapid internalization in CHO-K1 or HEK-293 cells as reported for CB1 
receptor internalization in AtT20 (Hsieh, Brown et al. 1999) and HEK-293 cells 
(Leterrier, Bonnard et al. 2004). Similar observations with slow internalization of CB2 
receptors were also made in Prof. Ken Mackies lab with CB2 transfected HEK-293 
cells or CHO-K1 cells (personal communication). These differences in the CB1 and 
CB2 receptor internalization could be receptor subtype specific and cell type 
dependant. Recently, developed commercial CB2 Redistribution® assay (BioImage 
Inc., Dec. 2007) employs a similar CB2 fusion with eGFP protein using a human 
osteosarcoma U2OS cell line (BioImage product). The authors of this assay used 
relatively long stimulation period for the internalization (1 h) further supporting my 
observations of slower internalization of CB2 receptors. In studies with human CB2-
myc tagged receptor, the authors also incubated CHO cells for relatively long time (1-
3 h) with agonists before investigating internalization by using FACS analysis 
(Bouaboula, Dussossoy et al. 1999). We can therefore conclude that CB2 receptor is 
not rapidly internalized as compared to that of CB1 receptor.  
Thus in summary, I showed that my in vitro expression system expressed intact CB2-
eCFP tagged protein. The fused receptors showed an equal extent of Erk-MAPK 
phosphorylation upon an agonist and antagonist treatment to that of CB2 receptors. 
Plasma membrane and intracellular CB2-eCFP fluorescent expression on was similar 
to that of reported expression pattern of CB1 receptors. The CB2-eCFP receptor 
undergoes agonist dependent internalization and co-incubation with CB2 receptor 
antagonist reversed this effect. Thus C-terminal tagging resulted into functional CB2 
receptor, which may lead to a marker for microscopic visualization of cells and for 
studies involving this receptor. For example small molecules and the newly identified 
compounds can be easily screened for their efficacies using this system. 
After confirming unaltered functionality in C-terminal tagged CB2 receptor, a similar 
knock-in constructs for CB2-eCFP and CB2-eGFP were generated (Fig. 4.19). I have 
used a homolologous 2.5 kb short arm of 5´ UTR sequence of CB2 sequence and a 
long arm of 6.4 kb of 3´ UTR region of CB2 for the homologous recombination in this 
construct. I kept the C-terminal fusion of the CB2 protein with eCFP or eGFP exactly 
identical to that I used for the cell culture studies. 
After transfection of ES cells with the target construct CB2-eCFP and CB2-eGFP 
(Tab. 4.2) about 10% homologous recombinated clones were found. This frequency 
is relatively high as compared to the reported frequency (1-3%) for homologous 
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recombination (Capecchi 1989). Studies by Thomas and Capecchi have suggested 
an exponential relationship between target homology and targeting frequency with 
insertion and replacement vectors (Thomas and Capecchi 1987). However, another 
study observed a linear relationship between the length of homology and the 
targeting frequency (Shulman, Nissen et al. 1990). Although it is difficult to compare 
the results of the above experiments directly, the discrepancy might arise from a 
difference in the targeted genomic regions.  
The amount of ES cell contribution to chimeric animal is largely dependent on the 
quality of cell line and can vary significantly between individual clones. It is also 
dependent on the genetic background of host embryo (Hogen, Beddington et al. 
1994). Thus I had used 2 different ES cell origins as well as different positively 
recombinated ES cell clones for microinjection (Tab. 4.3). 
I had obtained different chimeras with the R1 and MPI2 ES cell backgrounds in CD1 
and C57Bl/6J animals respectively. The percentage of chimeras was in range of 5-
70%, which shows that the ES cells used did not get effectively into every tissue. 
Inline with these observations, only in one chimeric animal with R1 ES cell 
background, CB2-eCFP germ line transmission was observed. Even in this chimeric 
animal the germ line transmission rate was very low. Only three germ line 
transmissions per 120 progenies were obtained. Out of these three germ line 
transmissions only one animal contained the desired gene of interest. Although 
majority of founders transmit the transgene to 50% of their offsprings, approximately 
20-30% of the founders mosaics transmit the transgene at a lower frequency to 5-
10% or not at all (Wilkie, Brinster et al. 1986; Longo, Bygrave et al. 1997; Suzuki, 
Kamada et al. 1997). It is known that in inbred mouse strains, such as C57BL/6J, ES 
cell lines colonize extensively, but in outbred strains such as CD1, ES cell poorly 
colonize (Zimmer 1992). However, until now, I had not obtained any other germ line 
transmission with the CB2-eGFP or CB2-eCFP chimeric animals. One possible 
reason for this could be that ES cells could have not colonized properly in mice 
strains.  
To avoid possible influence of neomycin gene in knock-in mice containing Cnr2-
eCFP-neo allele, these mice were paired with the transgenic mouse strain with early 
and uniform expression of the Cre site-specific recombinase. In this strain, PGK-
Crem, the early acting PGK-1 promoter drives Cre, but, probably due to cis effects at 
the integration site, the recombinase is under dominant maternal control (Lallemand, 
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Luria et al. 1998). This resulted in the deletion of neomycin gene, which was verified 
using PCR and Southern blot analysis (Fig. 4.25, Fig. 4.27). Obtained heterozygous 
animals were further paired to generate homozygous animals. The transmission of 
the knock-in gene followed proper Mendelian population distribution (Tab. 4.5). 
 
5.3 Expression analysis of CB2-eCFP knock-in mice 
The generated knock-in mice were further analyzed for the expression of fusion 
proteins. Based on initial in situ hybridization studies, it was apparent that CB2 has a 
rather defined expression in peripheral immune cells and multiple lymphoid organs. 
CB2 mRNA is found in spleen, tonsils, bone marrow, mast cells, peripheral blood 
leukocytes, and a variety of hemopoietic cell lines, including the myeloid cell line 
U937 and HL-60 cells. Thus, I analyzed these tissues for CB2-eCFP fluorescence. I 
had used different fluorescent microscopes and confocal microscopes for 
visualization of tissue sections to rule out instrumental error or due to use of GFP 
filter set for visualization of eCFP. However, I could not observe specific fluorescence 
over the autofluorescence exhibited by these organs (Fig. 4.30-31). 
Autofluorescence spectra are generally broad and encompass most of the visible 
spectral range, overlapping the emission wavelengths of green fluorescence protein 
and its many derivatives like eGFP and eCFP (Billinton and Knight 2001). When 
measuring fluorescence, the presence of autofluorescence often leads to low signal-
to-noise ratios, and can even fail to detect or visualize at all. Autofluorescence also 
reduce the contrast and clarity of fluorescent-labelled structures. Natural 
fluorescence in organs is due in large part to substances like flavins, lipofuscins 
(Schnell, Staines et al. 1999), elastin (Deyl, Macek et al. 1980), collagens and 
porphyrins in organs (Svanberg, Kjellen et al. 1986). Moreover, autofluorescence can 
also arise due to cellular media or type of fixative method used (Stewart, Villasmil et 
al. 2007). Thus, I had used different methods of fixation, including the method used 
for the detection of eGFP tagged delta opioid receptor (Scherrer, Tryoen-Toth et al. 
2006). Unfortunately, I could not observe specific CB2-eCFP fluorescence. Elowitz et 
al. found that a variety of GFPs, including eGFP, could undergo a photoconversion to 
a red fluorescent species upon irradiation with blue light, from an argon-ion laser or 
microscope lamp, under anaerobic conditions (Elowitz, Surette et al. 1997). The red 
fluorescent species thus formed absorbs green fluorescent light at 525 nm and 
fluoresces with a maximum at 600 nm. Thus GFP photoactivated in this way can be 
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viewed using a rhodamine filter set. Thus, I had also observed both the filters but 
found no difference in fluorescence pattern in wild type and CB2-eCFP tagged 
fluorescent mice.  
Considering the possibility of very low-level expression and high autofluorescence, I 
used more sensitive FACS detection method for analysis. Even in the isolated 
splenocytes and in peritoneal and bone marrow derived macrophages from the 
homozygous mice revealed no presence of tagged CB2 receptors. All the findings 
point towards the absence of the fusion protein in these cells.  
I further examined protein level expression of fusion protein using 
immunoprecipitation with GFP antibody. Unfortunately, in contrast to the cell culture 
overexpression studies (Fig. 4.9) I could not detect the CB2-eCFP fusion proteins in 
spleen and thymus (Fig. 4.33). Though, a very weak band of required size appeared 
in lymph nodes, which may indicate very low-level expression of protein. All these 
observations indicate that CB2 fusion receptor is not expressed in detectable level. 
Further, I wanted to observe the expression of the fusion transcript at RNA level. 
Thus, I analyzed bone marrow differentiated macrophages and dendritic cells, 
splenocytes, thymus and lymph nodes for the expression of CB2-eCFP transcripts 
(Fig. 4.34). I observed the presence of the fusion transcript in all tissues. Therefore, 
the lack of CB2-eCFP expression might be due to the change in CB2 reading frame 
or incorporation of stopcodon in knock-in locus. However, sequence analysis of 
amplified PCR product showed no mutations. CB2 fusion with fluorescent proteins by 
linker can also cause incorporation of the additional splice site. Analysis for additional 
splice sites did not reveal any additional splice sites incorporated, which could have 
affected protein translation. Additionally incorporated loxP site in 3' UTR region might 
interfere with the translation of CB2-eCFP protein. However, CB2-eCFP fusion 
transcript was present; hence, it is more likely that translation of the fusion protein in 
in vivo system was affected.  
Another possible reason for not observing fluorescence could be caused by low level 
of CB2 receptor in vivo. In model systems, neuropathy pain (data unpublished) and 
contact hypersensitivity (Karsak, Gaffal et al. 2007) increased CB2 mRNA expression 
was observed. This increase may also result in the increase of CB2 protein.  Thus, I 
had used these models for visualization of CB2-eCFP protein in CB2-eCFP 
homozygous mice. Unfortunately even in these models, I could not observe specific 
eCFP fluorescence. 
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In summary, absence or very low expression level of CB2-eCFP protein resulted into 
no specific fluorescence in the knock-in mice. This was verified by macroscopic and 
microscopic visualizations, by FACS analysis and immunoprecipitation with GFP 
antibody. However, in mRNA analysis CB2-eCFP transcript was observed. This 
indicates that CB2-eCFP was transcribed correctly. Amplified cDNA product for the 
CB2-eCFP fusion was sequenced and found to be identical to the expected 
sequence. Moreover, GFP immunoprecipation did not reveal CB2-eCFP fusion band 
in in vivo system. Together these observations indicate that either the CB2-eCFP 
mRNA translation or the stability of the fusion protein might have been affected in the 
knock-in mice.  
Alternate approaches for stable expression of CB2 fusion protein in in vivo system 
would be to use additional promoter or Kozak sequence or CB2 poly-A sequence to 
CB2 sequence. One can also employ the monoallelic replacement of gene of interest 
by a fluorescent tagged protein (Alferink, Lieberam et al. 2003). However, such 
pseudo knock-out mice will help us to understand only the expression of CB2 protein 
but not the functionality of CB2 protein. Moreover, to study receptor mechanism in 
real time, fluorescent ligands can also be used. These ligands would also provide 
additional insights into the receptor mediated signal transduction and cellular 
biochemistry of endocannabinoid system. Recently, such ligands for the cannabinoid 
receptors have been synthesized by Prof. Alexandros Makriyannis laboratory 
(personal communication). Further, stability and detection of these ligands in living 
system needs to be investigated. 
So far there are only two known eGFP tagged knock-in mice models reported for 
GPCRs, delta opioid receptor (Scherrer, Tryoen-Toth et al. 2006) and human 
rhodopsin (Chan, Bradley et al. 2004).  During this work, chimeras with eGFP tagged 
CB2 receptor have also been generated. Since eGFP has about 3 times stronger 
fluorescence intensity to that of the eCFP, we expect these eGFP knock-in mice 
might yield a stronger and specific fluorescence and will help us to visualize CB2 
receptor in in vivo. 
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6 Summary 
 
The endocannabinoid system performs various regulatory functions and has been 
implicated in a growing number of physiological roles. In an animal model for 
cutaneous contact hypersensitivity (CHS), we show that mice lacking both known 
cannabinoid receptors display exacerbated allergic inflammation. Cannabinoid 
receptor antagonists increased allergic inflammation, whereas receptor agonists 
attenuated inflammation.  
The results with CHS demonstrate a protective role of the endocannabinoid system 
in contact allergy in the skin and suggest a target for therapeutic intervention. 
 Unfortunately, it is difficult to assess CB2 receptor expression by immunostaining, 
because we still often observe immunostaining in tissues from CB2 knock-out mice. 
To overcome this problem the aim of this work was to generate mice with fluorescent 
tagged CB2 receptors.  
During this work various cell lines expressing murine CB2, CB2-eCFP and CB2-
eGFP receptors were generated. The cellular distribution and localization of the 
fusion proteins was analyzed by fluorescence microscopy. Furthermore, agonist 
dependent Erk-MAPK phosphorylation using CB2 and CB2-eCFP cell lines was also 
studied. 
The fusion protein was found to be localized in the cell membrane as well as in 
intracellular compartments. This pattern was strikingly analogous to the one 
observed with a similar CB1-eGFP fusion protein, indicating that the fusion does not 
change cellular localization. 
To determine whether downstream signalling pathways were affected by the C-
terminal fusion, CB2 and CB2-eCFP expressing CHO cells were treated with 
increasing concentrations of the CB2 specific agonist HU-308. A similar pattern of 
phosphorylation was observed, indicating that the downstream signalling was not 
altered.  
Having established that fluorescence tagging does not affect functionality of CB2 
receptor; CB2-eCFP and CB2-eGFP knock-in mice were generated. Unfortunately, 
only a weak mRNA expression for CB2-eCFP in spleen, lymph nodes and thymus, 
and either no or a very low CB2-eCFP protein expression by immunoprecipitation 
was observed. No CB2-eCFP expression was found in peritoneal and bone marrow 
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derived macrophages, dendritic cells, splenocytes, and lymph node cells by FACS 
analysis, and also no specific fluorescence in tissue sections of spleen, lymph node, 
spinal cord, and thymus.  
The in-vitro experiments indicate that the functionality of the CB2 receptor was not 
altered by eCFP fusion. Thus, the tagging strategy should to be useful for the 
detection of CB2 receptors in living cells or tissues. However, the very weak 
expression of CB2-eCFP receptors in  knock-in mice indicates that the fusion affects 
expression at translation level and/or stability of the modified protein. During this 
work, CB2-eGFP knock-in mice were also generated, which are under current 
analysis. 
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